Poster Presentations Session IV
Poster Presentations Session IV Tuesday, 7 November 2017
POSTERS SET-UP: 15:15 - 15:30
POSTERS DISPLAY HOURS: 15:30 - 19:15
POSTER AUTHOR DISCUSSION: 18:15 - 19:15
POSTERS DISMANTLE: 19:15


Poster display locations are shown below the poster codes
HEALTH CARE USE & POLICY STUDIES - Consumer Role in Health Care
PHP1
A1
UNDERSTANDING STAKEHOLDER EXPECTATIONS FOR PATIENT ENGAGEMENT: A QUALITATIVE SURVEY
Boudes M1, Robinson P2, Bertelsen N3, Brooke N4, Sargeant I4
1EURORDIS-Rare Diseases Europe, Paris, France, 2Merck Sharp & Dohme Ltd, Hoddesdon, UK, 3Neil Bertelsen Consulting, Berlin, Germany, 4The Synergist, Brussels, Belgium

PHP2
A2
UNDERSTANDING HTA AND PATIENT ENGAGEMENT: EFFECT OF INTEGRATING EXPERIENTIAL AND KNOWLEDGE LEARNING MODULES
Sandhu G1, Holtorf A2, Dresler M3
1Gurmit Sandhu Consulting GmbH, Basel, Switzerland, 2Health Outcomes Strategies GmbH, Basel, Switzerland, 3Suite 996, Basel, Switzerland

PHP3
A3
CONSUMER COMMENTS IN HEALTH TECHNOLOGY ASSESSMENT IN AUSTRALIA: HOW COMMON AND INFLUENTIAL ARE THEY?
Viswambaram A1, McManus K2, Miah R2, Miles G1
1Costello Medical Singapore Pte Ltd, Singapore, Singapore, 2Costello Medical Consulting Ltd, Cambridge, UK

HEALTH CARE USE & POLICY STUDIES - Diagnosis Related Group
PHP4
A4
THE ANALYSIS OF THE NUMBER OF SAME-DAY SURGERY CASES IN 2015 IN HUNGARIAN HOSPITALS
Pónusz R, Németh N, Kovács D, Endrei D, Boncz I
University of Pécs, Pécs, Hungary

PHP5
A5
WITHDRAWN

HEALTH CARE USE & POLICY STUDIES - Disease Management
PHP6
A6
MULTIPLE CHRONIC CONDITIONS IN OLDER PEOPLE AND THEIR EFFECTS ON HEALTH CARE UTILIZATION: A NETWORK ANALYSIS APPROACH USING SHARE DATA
Srakar A1, Prevolnik Rupel V2
1Institute for Economic Research, Ljubljana and Faculty of Economics, University of Ljubljana, Ljubljana, Slovenia, 2Institute for Economic Research, Ljubljana, Slovenia

PHP7
A7
THE PRACTICAL APPLICATION OF A DIGITAL THERAPEUTIC EDUCATION PLATFORM FOR CARDIOVASCULAR REHABILITATION
Abdennbi K1, Bader J2, Atellian L2
1Hôpital Léopold Bellan, Paris, France, 2Observia, Paris, France

PHP8
A8
EVALUATION FRAMEWORK FOR DIGITAL MEDICINES IN EUROPE
Krishnan A, Schmitz S
Partners4Access, LONDON, UK

PHP9
A9
ARE PHARMACEUTICAL COMPANIES PRIORITIZING MULTI-INDICATION DRUGS?
Lurie BF1, Rubinstein J2, Rubinstein ER1, Rosenblum SB3, Ho Y1
1Context Matters, New York, NY, USA, 2Context Matters (A Decision Resources Group Company), New York, NY, USA, 3Context Matters, Inc., New York, NY, USA

PHP10
A10
RACIAL DISPARITIES IN TREATMENT OF PREGNANT WOMEN WITH DRUG USE, ABUSE AND DEPENDENCE
Patel I1, Kalkat S2, Kwerteng E2, Onigbinde I2, Han Y3
1Marshall University, Huntington, VA, USA, 2Shenandoah University, Winchester, VA, USA, 3University of Michigan, Ann Arbor, MI, USA

PHP11
A11
RECENT TRENDS IN PROVIDER PERCEPTIONS AND USE OF VALUE FRAMEWORKS IN THE UNITED STATES (US)
Brown D1, Campbell C2, Migliaccio-Walle K1, Jackson J2, Meyer K2
1Xcenda, LLC, Palm Harbor, FL, USA, 2Xcenda, Palm Harbor, FL, USA

PHP12
A12
ADULT RISK FACTORS OF NONCOMMUNICABLE DISEASE OUTCOMES
Cinaroglu S1, Baser O2
1Hacettepe University, Ankara, Turkey, 2Columbia University and STATinMED Research, New York, NY, USA

HEALTH CARE USE & POLICY STUDIES - Drug/Device/Diagnostic Use & Policy
PHP13
A13
COMPARATIVE ANALYSIS OF MEDICINE'S PURCHASSING PRICES OF "ADDITIONAL LIST"(APHP VERSUS FRENCH HOSPITALS FORMELY UNDER OVERALL ALLOCATION)
Doffou E1, Degrassat-Theas A2, Paubel P3
1Teaching Hospital of Yopougon (Côte d'Ivoire), Abidjan, Cote d'Ivoire, 2Assistance publique des hôpitaux de Paris, Paris, France, 3Université Paris sorbonne Cité, Paris, France

PHP14
A14
VARYING NATURE OF THE ASSESSMENT OF ADVANCED MEDICINAL PRODUCTS (ATMP) IN GERMANY
Volmer T, Bakker K
SmartStep Consulting GmbH, Hamburg, Germany

PHP15
A15
EARLY ACCESS TO MEDICINES PATHWAYS – RESULTS OF A GLOBAL SURVEY
Mills M, Efthymiadou O, Tzouma V, Grimaccia F, Kanavos P
London School of Economics and Political Science, London, UK

PHP16
A16
FACTORS INFLUENCING INNOVATIVE DRUG REIMBURSEMENT IN POLAND
Skora K, Augustynska J, Walczak J
Arcana Institute Ltd, Krakow, Poland

PHP17
A17
HOW WELL DOES THE LEADING PHARMACEUTICAL REFORM MODEL WORK IN CHINA? --AN INTERRUPTED TIME SERIES ANALYSIS
He Y
Fudan University, Shanghai, China

PHP18
A18
TRENDS IN EMERGING NON-HTA DRUG VALUE ASSESSMENT FRAMEWORKS
Lach K1, Kloc K1, Chouaid C2, Borget I3, Rémuzat C4, Toumi M5
1Creativ-Ceutical, Krakow, Poland, 2Centre Hospitalier Intercommunal, DHU-ATVB, Département de Pneumologie et Pathologie Professionnelle, Créteil, France, 3Gustave Roussy, Villejuif, France, 4Creativ-Ceutical, Paris, France, 5Aix-Marseille University, Marseille, France

PHP19
A19
TIME RESTRICTED DECISIONS IN GERMAN BENEFIT ASSESSMENTS – A SUCCESS STORY?
Penner E, Boehler Y
TH Koeln, University of Applied Sciences, Leverkusen, Germany

PHP20
A20
PRICING AND TIME-TO-MARKET FOR MONOCLONAL ANTIBODIES IN ITALY
Vanelli ME1, Marocco A2, Stanisic S2, Berto P3
1SDA Bocconi School of Management, Milano, Italy, 2Analytica Laser, Milan, Italy, 3Analytica LASER, Milan, Italy

PHP21
A21
REAL WORLD EVIDENCE IN EUROPE - THE RESULTS OF AN EXPERT SURVEY
Gill JL1, Albanell J2, Avouac B3, Dank M4, Duncombe R5, Fink-Wagner A6, Hutton J7, Jahnz-Rozyk K8, Kössler I9, Podrazilova K10, Schramm W11, Spandonaro F12, Vaz Carneiro A13, Wartenberg M14, Kanavos P1
1London School of Economics and Political Science, London, UK, 2Hospital del Mar, Barcelona, Spain, 3Medecin des Hopitaux de Paris, Paris, France, 4Semmelweis University, Budapest, Hungary, 5The Christie NHS Foundation Trust, Manchester, UK, 6Global Allergy and Asthma Patient Organisation, Vienna, Austria, 7University of York, York, UK, 8Military Institute of Medicine, Warsaw, Poland, 9Swedish Breast society, Boras, Sweden, 10Association of Health Insurance Companies, Prague, Czech Republic, 11University of Munich and Rudolf Marx Stiftung, Munich, Germany, 12University of Rome Tor Vergata, Rome, Italy, 13Center for Evidence Based Medicine, Faculty of Medicine, University of Lisbon, Lisbon, Portugal, 14Sarcoma Patients EuroNet Association, Wölfersheim, Germany

PHP22
A22
MEASURING THE IMPACT OF THE FOOD AND DRUG ADMINISTRATION (FDA) UNAPPROVED DRUG INITIATIVE (UDI) ON DRUG PRICES AND EXPENDITURES
Sharma D1, Schumock G2, Saffore CD3, Walton SM4
1University of Illinois at Chicago, Chicago, IL, USA, 2University of Illinois at Chicago College of Pharmacy, Chicago, IL, USA, 3Department of Pharmacy Systems, Outcomes and Policy, University of Illinois at Chicago, Chicago, IL, USA, 4University of Illinois at Chicago, Chicago, MA, USA

PHP23
A23
PRICE COMPARISON OF NEW DRUGS IN JAPAN, EU AND US
Maruyama M, Tsujimura K, Kasahara M, Yamabe K
Takeda Pharmaceutical Company Limited, Tokyo, Japan

PHP24
A24
ATTITUDES TOWARDS GENERIC SUBSTITUTION IN GREECE
Kyriopoulos D1, Kyriopoulos I2, Athanasakis K1
1National School of Public Health, Athens, Greece, 2London School of Economics and Political Science, London, UK

PHP25
A25
EVALUATING PATIENTS’, PHYSICIANS’ AND PHARMACISTS’ PERCEPTION REGARDING GENERIC MEDICINES IN ETHIOPIA: FINDINGS AND IMPLICATIONS
Erku DA1, Gebresillassie BM2, Tefera YG3, Belachew SA1, Abebe TB1, Haile KT1, Mekuria Ab1
1University of Gondar, Gondar, Ethiopia, 2university of gondar, gondar, Ethiopia, 3University of Gondar, City, Ethiopia

PHP26
A26
OPEN TO THE PUBLIC? A COMPARATIVE ANALYSIS OF DATA PUBLISHED UNDER THE “EMA POLICY ON THE PUBLICATION OF CLINICAL DATA” AND DOSSIERS FOR EARLY BENEFIT ASSESSMENTS IN GERMANY
El Ouardani W, Boehler Y
TH Koeln, University of Applied Sciences, Leverkusen, Germany

PHP27
A27
MEDICINE PRICES DISPARITY AMONG RETAIL PHARMACIES IN SELANGOR, MALAYSIA
Lim YW1, Neoh CF2, Lee KS1, Tan CS3, Khan TM4, Long CM5
1Pharmaceutical Services Division, Ministry of Health, Malaysia, Petaling Jaya, Malaysia, 2Universiti Teknologi MARA, Malaysia, Shah Alam, Malaysia, 3KPJ International College, Bukit Mertajam, Malaysia, 4Monash University Malaysia, Subang Jaya, Malaysia, 5University of Tasmania, Hobart, Australia

PHP28
B1
PRICING PANTOPRAZOLE IN GREECE: A TALE OF DISTORTION
Ollandezos M, Papadopoulos K, Pentafragka E, Stefanidou Z
Panhellenic Association of Pharmaceutical Industry, Athens, Greece

PHP29
B2
DEMAND AND SUPPLY SIDE REGULATION OF BIOSIMILAR MARKETS IN GERMANY, FRANCE AND ENGLAND AND ITS IMPLICATIONS FOR MARKET ACCESS OF BIOSIMILARS
Walendzik A1, Altin S2, Wasem J2
1University Duisburg-Essen, Essen, Germany, 2University of Duisburg-Essen, Essen, Germany

PHP30
B3
PRICING REGULATION FOR GENERICS IN GREECE: THE CASE OF ATORVASTATIN.
Stefanidou Z, Papadopoulos K, Pentafragka E, Ollandezos M
Panhellenic Association of Pharmaceutical Industry, Athens, Greece

PHP31
B4
THE RESEARCH AND SUGGESTIONS ON THE ACCESSIBILITY OF HIGH VALUE DRUGS IN CHINA
SHI H1, Xu L2, Huang L2
1Astrazeneca(China), Beijing, China, 2Astrazeneca (China), Beijing, China

PHP32
B5
E-HEALTH FUNDING IN EUROPE
Young KE1, Soussi I2, Kornfeld M1, Toumi M3
1Creativ-Ceutical, Paris, France, 2Creativ-Ceutical, Tunis, Tunisia, 3Aix-Marseille University, Marseille, France

PHP33
B6
COMPARISON OF FOOD AND DRUG ADMINISTRATION, EUROPEAN MEDICINE AGENCY AND SWISSMEDIC NEW DRUG APPROVAL: AN ASSESSMENT OF THE INTERNATIONAL HARMONIZATION
Zeukeng M1, Seoane-Vazquez E2
1University of Geneva, Geneva, Switzerland, 2Chapman University, Irvine, CA, USA

PHP34
B7
INNOVATIVE CONTRACTING: USE OF COMPLEX MANAGED ENTRY AGREEMENTS
Privolnev Y
Decision Resources Group, Toronto, ON, Canada

PHP35
B8
FACTORS RELATED TO OUTPATIENT ANTIBIOTIC DRUG CONSUMPTION IN TURKEY
Cinaroglu S1, Baser O2
1Hacettepe University, Ankara, Turkey, 2Columbia University and STATinMED Research, New York, NY, USA

PHP36
B9
WITHDRAWN

PHP37
B10
PROBABILISTIC SENSITIVITY ANALYSIS AND ITS ROLE IN ASSESSMENT OF PROFITABILITY IN POLAND
Pieniazek I, Goc M, Walczak J
Arcana Institute Ltd, Krakow, Poland

PHP38
B11
WITHDRAWN

PHP39
B12
WITHDRAWN

PHP40
B13
ACCELERATED UPTAKE OF INNOVATIVE HEALTH TECHNOLOGIES: A LITERATURE REVIEW
Cowell W1, Ovseiko P2, Lee J3, Ford G4
1Janssen Inc., High Wycombe, UK, 2John Radcliffe Hospital, Oxford, UK, 3Janssen UK, High Wycombe, UK, 4Oxford Academic Health Science Network, Oxford, UK

PHP41
B14
CAN EARLY ACCESS SUPPORT CONTINUED ACCESS? THE RELATIONSHIP BETWEEN EAMS AND NICE
Walsh SC1, Cosentino L2, Macaulay R1
1PAREXEL International, London, UK, 2PAREXEL International, Horsham, PA, USA

PHP42
B15
THE INFLUENCE OF PHARMACEUTICAL REFORM IN KOREA A DECADE AGO: WHAT WE WALKED
Na Y1, Oh R1, Kim H2, Ryu M1
1HIRA (Health Insurance Review & Assessment Service), Wonju-si, Gangwon-do, Korea, Republic of (South), 2HIRA (Health Insurance Review & Assessment Service), Gangwon-do, Korea, Republic of (South)

PHP43
B16
EXPENDITURE ON NON-PHARMACEUTICAL PRODUCTS IN IRELAND DURING A PERIOD OF HEALTHCARE COST CONTAINMENT
Carney P, Corless S
Novartis Ireland Ltd., Dublin 4, Ireland

PHP44
B17
POTENTIAL FUNDING SOURCES FOR BREAKTHROUGH THERAPIES
Hanna E1, Remuzat C2, Auquier P1, Dussart C3, Toumi M1
1Aix-Marseille University, Marseille, France, 2Creativ-Ceutical, Paris, France, 3Lyon 1 University, Lyon, France

PHP45
B18
NEW DRUGS APPROVAL IN ITALY: ANALYSIS OF THE APPLIED NEGOTIATION CONDITIONS 2015-2017
Lidonnici D, Lanati EP, Isernia M
MA Provider Srl, Milano, Italy

PHP46
B19
NEW DRUGS APPROVAL TIMING IN ITALY (2015-2017)
Lidonnici D, Lanati EP, Isernia M
MA Provider Srl, Milano, Italy

PHP47
B20
GENE-THERAPY, THE WAY FORWARD IN EUROPE – THE PAYER PERSPECTIVE
Poschen C, Schmitz S, Krishnan A
Partners4Access, LONDON, UK

PHP48
B21
ORPHAN DRUGS IN THE UK, DO THEY MEET THE NICE HIGHLY SPECIALISED TECHNOLOGY THRESHOLD?
Weinstein N, Martin M, Campbell R
inVentiv Health, London, UK

PHP49
B22
NICE’S NEW BUDGET IMPACT THRESHOLD – WHAT PROPORTION OF DRUGS IS THIS LIKELY TO AFFECT?
Macaulay R, Shaw S, Dave K, Tang M
PAREXEL International, London, UK

PHP50
B23
PRICE LIFE CYCLE MANAGEMENT OF ORPHAN DRUGS IN FRANCE
Lebreton C1, Avot D2, Morand F1, Laigle V3, Troubat A1
1QuintilesIMS, Paris La Defense, France, 2MSD France, Courbevoie, France, 3MSD Vaccins, Lyon, France

PHP51
B24
AVOIDING A MARKET FOR LEMONS WITH PHARMACEUTICALS: HOW RISK-SHARING MECHANISMS CAN IMPROVE ALLOCATION
Brammli-Greenberg S1, Daniels E2, Yaari I2
1University of Haifa, Haifa, Israel, 2Myers-JDC-Brookdale Institute, Jerusalem, Israel

PHP52
B25
USE OF PRAGMATIC CLINICAL TRIALS TO SUPPORT DRUG LAUNCH
Rémuzat C1, Kloc K2, Toumi M3
1Creativ-Ceutical, Paris, France, 2Creativ-Ceutical, Krakow, Poland, 3Aix-Marseille University, Marseille, France

PHP53
B26
A TYPOLOGY-BASED DECISIONAL FRAMEWORK TO SUPPORT MARKET ACCESS AND REIMBURSEMENT DECISIONS FOR PERSONALISED MEDICINES
Govaerts L1, Geldof T1, Simoens S1, Huys I1, Van Dyck W2
1KU Leuven, Leuven, Belgium, 2Vlerick Business School, Brussels, Belgium

PHP54
B27
RELAXING RULES FOR PHARMACEUTICALS AND BENEFIT COVERAGE EXPANSION IN KOREA: THE IMPACT ON THE PHARMACEUTICAL EXPENDITURE
Oh R, Na Y
HIRA (Health Insurance Review & Assessment Service), Wonju-si, Gangwon-do, Korea, Republic of (South)

PHP55
C1
EARLY ACESS BUT THEN WHAT? THE UK EARLY ACCESS TO MEDICINES SCHEME THREE YEAR REPORT CARD
Macaulay R
PAREXEL International, London, UK

PHP56
C2
IDENTIFICATION OF IMPORTANT CRITERIA FOR DRUG REIMBURSEMENT DECISION-MAKING AND THEIR RELATIVE IMPORTANCE
Funagoshi M, Murasawa H, Shimozuma K
Ritsumeikan University, Kusatsu, Japan

PHP57
C3
REVIEW OF THE REIMBURSEMENT ENVIRONMENT FOR ADVANCED THERAPEUTIC MEDICINAL PRODUCTS (ATMPS) IN THE UK
Hughes T, Harries M, Sattar S
MAP BioPharma Limited, Cambridge, UK

PHP58
C4
INVESTIGATING COMPARATOR REQUIREMENTS FOR DRUG SELECTION FOR COST-EFFECTIVENESS
Benisheva T1, Cherneva D1, Vodenicharov Z1, Boncheva E2, Kralimarkov N1
1Faculty of Public Health Medical University - Sofia, Bulgaria, Sofia, Bulgaria, 2Bulgarian Association for Drug Information, Sofia, Bulgaria

PHP59
C5
TRENDS IN FDA DRUG PROMOTION ENFORCEMENT LETTERS OVER A TEN-YEAR PERIOD
Zagrodney K1, Sheikhan T2, Sheikhan NY3, Pinto AM3, Witek T1
1University of Toronto, Toronto, ON, Canada, 2University College London, London, UK, 3McMaster University, Hamilton, ON, Canada

PHP60
C6
HEALTH TECHNOLOGY ASSESSMENT IN SINGAPORE: SHINING A LIGHT IN THE DARKNESS
Viswambaram A, Brooks-Rooney C
Costello Medical Singapore Pte Ltd, Singapore, Singapore

PHP61
C7
EUROPEAN INITIATIVES TO ENHANCE BIOSIMILAR ADOPTION
Kapuśniak A1, Rémuzat C2, Toumi M3
1Creativ-Ceutical, Kraków, Poland, 2Creativ-Ceutical, Paris, France, 3Aix-Marseille University, Marseille, France

PHP62
C8
GENERICS POLICIES: A SYSTEMATIC REVIEW OF THEIR EFFECTIVENESS
Braoudaki E, Naoum V, Karampli E, Athanasakis K, Kyriopoulos J
National School of Public Health, Athens, Greece

PHP63
C9
MECHANISMS OF TRADE MARGIN REGULATION OF PRESCRIPTION DRUGS: COMPARISON OF 15 EU COUNTRIES
Kolbe K1, Zoellner YF2
1ECON-EPI, Düsseldorf, Germany, 2Hamburg University of Applied Sciences, Hamburg, Germany

PHP64
C10
ACCEPTANCE OF INDIRECT COMPARISONS IN THE GERMAN EARLY BENEFIT ASSESSMENT
Berkemeier F1, Bleß H1, Reindl S2, Ballhausen A3, Maltz A2
1IGES Institut GmbH, Berlin, Germany, 2IGES Institut GmbH, Nuremberg, Germany, 3IGES Institut GmbH, Hamburg, Germany

PHP65
C11
PRICING PRESSURES AND MARKET ACCESS OUTCOMES OF ADVANCED THERAPY MEDICINAL PRODUCTS (ATMPS) IN THE EU5
Jenkins MJ1, Borga P1, Ribeiro A2
1Lifescience Dynamics, London, UK, 2Lifescience Dynamics, Boston, MA, USA

PHP66
C12
HOUSEHOLD STORAGE OF MEDICINES AND ASSOCIATED FACTORS IN TIGRAY REGION, NORTHERN ETHIOPIA
Dagne AW
University of Groningen, Groningen, The Netherlands

PHP67
C13
THE UTILISATION OF BIOSIMILAR INFLIXIMAB BY ENGLISH ACUTE TRUSTS
Alnahar SA1, Elliott RA2, Waring J3
1Division of Pharmacy Practice and Policy, School of Pharmacy, University of Nottingham, Nottingham, UK, 2Manchester Centre for Health Economics, Division of Population Health, Health Services Research and Primary Care, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK, 3Centre for Health Innovation, Leadership and Learning (CHILL), Nottingham Business School, University of Nottingham, Nottingham, UK

PHP68
C14
DRUG UTILIZATION STUDY OF ANTIBACTERIAL IN THE MEDICAL INTENSIVE CARE UNIT (MICU) OF A CHITWAN MEDICAL COLLEGE TEACHING HOSPITAL(CMCTH), BHARATPUR, CHITWAN, NEPAL.
Luitel A, Marasine N, Gautam A, Baral S
Chitwan Medical College, Chitwan, Nepal

PHP69
C15
SEARCH OF HIGH ACTIVE AND LOW TOXIC NEWLY SYNTHESIZED DERIVATIVES OF PIPERIDINE FOR REGIONAL ANESTHESIA
Kadyrova D, Smagulova G, Kim I, Seitaliyeva A, Satbayeva E, Ananyeva L, Batagoeva Z
Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan

PHP70
C16
FORECASTING PHARMACEUTICAL EXPENDITURE IN EUROPE: ADJUSTING FOR THE IMPACT OF REBATES AND DISCOUNTS
Espin J1, Schlander M2, Godman B3, Anderson P4, Mestre-Ferrandiz J5, Hutchings A6, Flostrand S7, Parnaby A7
1Andalusian School of Public Health, Granada, Spain, 2University of Heidelberg/German Cancer Research Center (DKFZ), Heidelberg, Germany, 3Karolinska Institutet, Stockholm, Sweden, 4Swansea University, Swansea, UK, 5Independent economics consultant, Madrid, Spain, 6Dolon Ltd, London, UK, 7Celgene International, Boudry, Switzerland

PHP71
C17
PERSISTENCE AND CONCENTRATION OF PRESCRIPTION DRUG EXPENDITURE AMONG MEDICARE BENEFICIARIES 2006-2013
Xu Y, Joyce G
University of Southern California, Los Angeles, CA, USA

PHP72
C18
DIFFERENCES AND DECISION DRIVERS IN THE HTA-OUTCOME CATEGORY LOWER BENEFIT BETWEEN IQWIG AND G-BA ASSMENT IN THE GERMAN AMNOG PROCESS
von Hein M, Jakovac M, Peters A, Eheberg D
QuintilesIMS, Munich, Germany

HEALTH CARE USE & POLICY STUDIES - Equity and Access
PHP73
C19
INFLUENCE OF PEER PRESSURE MECHANISM ON QUALITY AND COSTS OF HEALTHCARE, ON EXAMPLES OF ISRAEL, FRANCE AND USA.
Rączka A, Hermanowski TR, Cegłowska U
Medical University of Warsaw, Warsaw, Poland

PHP74
C20
THE EFFECT OF POLICIES FOR IMPROVING THE ACCESS TO NEW MEDICINES IN SOUTH KOREA : A RETROSPECTIVE ANALYSIS IN 2007 - 2016
KIM E1, Lee E2
1UCB Korea, Seoul, Korea, Republic of (South), 2Sungkyunkwan University, Suwon-si, Gyeonggi-do, Korea, Republic of (South)

PHP75
C21
ACCESS TO ORPHAN DRUGS (ODS) IN SPAIN COMPARED WITH EU4 COUNTRIES: INEQUITY AND LACK OF PRICE TRANSPARENCY ACROSS EUROPE
Badia X, Gil A, Shepherd J, Guarga L
Omakase Consulting, Barcelona, Spain

PHP76
C22
IS THE DISCONNECT BETWEEN EUROPEAN MEMBER STATE CONTROLLED COMPASSIONATE USE PROGRAMS AND THE CENTRALISED EMA PROCESS CREATING AN EARLY ACCESS LOTTERY FOR PATIENTS?
Jones-Phillips DL, Bradshaw SE
Valid Insight, London, UK

PHP77
C23
EARLY ACCESS PROGRAMS; A USEFUL TOOL TO IMPROVE ACCESS FOR PATIENTS AND MANUFACTURERS
Gilbane A, Schlegel CR, Rupasinghe B, Dabor-Alloh D, Walsh K
Navigant Consulting, London, UK

PHP78
C24
EVOLUTION OF THE TIME-TO-MARKET OF HOSPITAL PRODUCTS IN SPAIN
Gómez-Navarro V1, Fraile S2, Solozabal M1
1QuintilesIMS, Barcelona, Spain, 2QuintilesIMS, Madrid, Spain

PHP79
C25
DAMNED IF YOU ‘D’? EVIDENCE THE SELECTION OF THE APPRAISAL COMMITTEE MAY AFFECT NICE TECHNOLOGY ASSESSMET OUTCOMES
Macaulay R1, Roibu C1, McCann E1, Tripathi S2, Chauhan E2, Berardi A1
1PAREXEL International, London, UK, 2PAREXEL International, Chandigarh, India

PHP80
C26
HOW TO MAINTAIN PHARMACEUTICAL ACCESS IN CRISIS: THE IRAN FDA EXPERIENCE
Yousefi N1, Peiravian F2, Dinarvand R3, Moradi N4, Ghiasi G4, Inanloo H4
1Shahid Beheshti university of medical Sciences, School of Pharmacy, Tehran, Iran, 2Shahid Beheshti University of Medical Sciences, School of Pharmacy, Tehran, Iran, 3Tehran university of medical sciences, Tehran, Iran (Islamic Republic of), 4Iran Food and Drug Organization, Tehran, Iran (Islamic Republic of)

PHP81
C27
THE IMPACT OF SCOTTISH MEDICINES CONSORTIUM (SMC) PROCESS CHANGES ON ACCEPTANCE RATES FOR NEW MEDICINES FOR END OF LIFE AND VERY RARE CONDITIONS
McMurray M, Downes N, Brown A, Lee A, Macdonald A, O'Toole B
Healthcare Improvement Scotland, Glasgow, UK

HEALTH CARE USE & POLICY STUDIES - Formulary Development
PHP82
D1
AN INTRODUCTIVE ANALYSIS OF THE TIMEFRAME FROM EUROPEAN DRUGS APPROVAL TO THE SICILIAN HOSPITAL FORMULARY INCLUSION
Aiello A1, D'Ausilio A1, Pizzimenti V2, Formica D2, Sultana J2, Lucchesi S3, Ientile V2, Toumi M4, Trifirò G3
1Creativ Ceutical, Milan, Italy, 2A.O.U. Policlinico “G. Martino”, Messina, Italy, 3University of Messina, Messina, Italy, 4Aix-Marseille University, Marseille, France

HEALTH CARE USE & POLICY STUDIES - Health Care Costs & Management
PHP83
D2
HAEMORRHOIDAL ARTERY LIGATION PROCEDURE FOR THE TREATMENT OF SYMPTOMATIC GRADE II–III HEAMORRHOIDS: A TRIAL-BASED AND LONG-TERM MODEL-BASED ECONOMIC EVALUATION
Alshreef A1, Wailoo A2
1University of Sheffield, Sheffield, UK, 2EuroQol Office, Rotterdam, The Netherlands

PHP84
D3
EMPIRICAL STUDIES ON THE ECONOMIC VALUE OF A STATISTICAL LIFE YEAR (VSLY) IN EUROPE: WHAT DO THEY TELL US?
Schlander M1, Schaefer R2, Schwarz O3
1University of Heidelberg/German Cancer Research Center (DKFZ), Heidelberg, Germany, 2Institute for Innovation & Valuation in Health Care (InnoVal-HC), Wiesbaden, Germany, 3Hochschule Heilbronn, Wiesbaden, Germany

PHP85
D4
COST-UTILITY ANALYSIS OF ROSUVASTATIN COMPARED TO ATORVASTATIN IN PRIMARY PREVENTION OF MYOCARDIAL INFARCTION AMONG HIV-POSITIVE PATIENTS ON HAART IN UGANDA
Serunjogi B, Lamorde M
Infectious Diseases Institute, Kampala, Uganda

PHP86
D5
A MODEL TO PREDICT COSTS AND OUTCOMES ASSOCIATED WITH HYPERKALAEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE OR HEART FAILURE
Bennett H1, Palaka E2, Ayoubkhani D1, Evans M3, McEwan P1, Bergenheim K4, Kim K5, Grandy S6
1Health Economics and Outcomes Research Ltd, Cardiff, UK, 2AstraZeneca, Cambridge, UK, 3University Hospital Llandough, Cardiff, UK, 4AstraZeneca, Gothenburg, Sweden, 5AstraZeneca, Södertälje, Sweden, 6Astrazeneca Phamaceuticals , LP, Gaithersburg, MD, USA

PHP87
D6
FACTORS CONTRIBUTING TO THE NATIONAL DRUG EXPENDITURE OF KOREA, 2010-2015: FOCUSING ON THE CORE THERAPEUTIC CLASSES
Oh R1, Na Y2, Ryu M2
1HIRA (Health Insurance Review & Assessment Service), Wonju-si, Gangwon-do, Korea, Republic of (South), 2Health Insurance Review & Assessment Service, Wonju-si, Gangwon-do, Korea, Republic of (South)

PHP88
D7
COSTS OF OWNERSHIP OF READY-TO-ADMINISTER PRE-FILLED STERILIZED SYRINGES IN A DUTCH HOSPITAL; A COST MINIMIZATION ANALYSIS
Larmene- Beld KH1, Spronk J1, Taxis K2, Postma MJ2
1Isala hospital, Zwolle, The Netherlands, 2University of Groningen, Groningen, The Netherlands

PHP89
D8
COMPARISON OF HOSPITAL RESOURCE UTILIZATION BETWEEN ELECTIVE AND EMERGENT ADMISSIONS AMONG PATIENTS UNDERGOING INPATIENT COLORECTAL SURGERY
Wei D1, Gutierrez M2, Goldstein LJ3, Johnston SS4
1Johnson and Johnson, New Brunswick, NJ, USA, 2Ethicon, Cincinnati, OH, USA, 3Johnson & Johnson, Markham, ON, Canada, 4Johnson & Johnson Co., New Brunswick, NJ, USA

PHP90
D9
ECONOMIC IMPACT OF NURSE SENSITIVE OUTCOMES IN IRISH HOSPITALS
Murphy A, Drennan J, Brady N, Dahy D
University College Cork, Cork, Ireland

PHP91
D10
DIFFERENCE BETWEEN ANNUAL NATIONAL HEALTH STATISTICS AND 1-COMPLETE-YEAR MEDICAL USE IN COST-ESTIMATION.
Hong S, Jang J, Nam JH, Song HJ, Park J, Lee E
School of Pharmacy, Sungkyunkwan University, Suwon, Korea, Republic of (South)

PHP92
D11
DRUGPRICE DEVELOPMENTS AFTER PATENT EXPIRY
Vondeling GT1, Cao Q2, Visser S3, Postma MJ2, Rozenbaum MH4
1University of Groningen, Zuidhorn, The Netherlands, 2University of Groningen, Groningen, The Netherlands, 3Datascientia, Groningen, The Netherlands, 4Pfizer NL, Capelle aan den IJssel, The Netherlands

PHP93
D12
THE ECONOMIC IMPACT OF FIBRIN SEALANTS USED FOR HEMOSTASIS IN CORONARY ARTERY BYPASS GRAFTING SURGERY; AN ITALIAN PERSPECTIVE
Parago V1, Jamous N2
1Johnson & Johnson Medical Devices, Pomezia, Italy, 2Johnson & Johnson Medical Ltd, Berkshire, UK

PHP94
D13
EVALUATING THE COST-UTILITY OF IMMUNOSUPPRESSIVE REGIMENS IN LIVER TRANSPLANT RECIPIENTS IN CANADA
Pollock RF1, Schwartz J2, Howell J3, Spalding J2
1Ossian Health Economics and Communications GmbH, Basel, Switzerland, 2Astellas Pharma Global Development, Inc., Northbrook, IL, USA, 3Astellas Pharma Global Development, Inc., Markham, ON, Canada

PHP95
D14
COST-EFFECTIVENESS OF A PHYSICAL ACTIVITY PROMOTION INTERVENTION FOR PEOPLE WITH DISABILITIES: A MARKOV MODEL APPROACH
Lee D, Lee Y, Oh I
Kyung Hee University, Seoul, Korea, Republic of (South)

PHP96
D15
INCREASING TREND ON TURKISH UN-LICENCED MEDICINE MARKET : A GENERAL OVERVIEW ANALYSIS
Kockaya G1, Yenilmez FB2, Sharaf A1, Ammar H1
1CarthaGenetics, Pully, Switzerland, 2Akıl Consultancy, London, UK

PHP97
D16
BUDGET IMPACT OF NEWLY APPROVED DRUGS BY THE SICILIAN DRUG FORMULARY COMMITTEE: AN INTRODUCTIVE ANALYSIS
Aiello A1, D'Ausilio A1, Pizzimenti V2, Formica D2, Sultana J2, Lucchesi S3, Ientile V2, Toumi M4, Trifirò G3
1Creativ Ceutical, Milan, Italy, 2A.O.U. Policlinico “G. Martino”, Messina, Italy, 3University of Messina, Messina, Italy, 4Aix-Marseille University, Marseille, France

PHP98
D17
BIOSIMILARS AND REFERENCE BIOTECHNOLOGIC DRUGS: COMPARISON OF THE BIOSIMILARS’ EFFECT ON REFERENCE DRUG’S PRICE FOR EU, USA AND TURKEY
Tuna E, Caliskan Z
Hacettepe University, Ankara, Turkey

PHP99
D18
IMPACT OF HEALTH POLICIES ON CATASTROPHIC HEALTH EXPENDITURES IN TURKEY
Kockaya G1, Tuncay B2, Aygun A3, Yildirim J4
1Beykent University, Istanbul, Turkey, 2Koc University, Istanbul, Turkey, 329 Mayıs University, Istanbul, Turkey, 4TED University, Ankara, Turkey

PHP100
D19
COST ANALYSIS OF DELIVERY NEONATAL DRUG THERAPY SERVICES AT MINISTRY OF HEALTH IN SAUDI ARABIA
Alomi YA1, Alhadab M2
1Ministry of Health, RIYADH, Saudi Arabia, 2Alyamama Hospital, RIYADH, Saudi Arabia

PHP101
D20
COST ANALYSIS OF DRUG-RELATED PROBELMS IN SAUDI ARABIA, PATIENT AND HEALTH CARE PROFESSIONAL'S PERSPECTIVE
Alomi YA, Al-Shaibani AS, Alfaisal G, Alasmi NM
Ministry of Health, RIYADH, Saudi Arabia

PHP102
D21
FLUOROQUINOLONE-RELATED ADVERSE EVENTS RESULTING IN HEALTH CARE USE AND COSTS: A SYSTEMATIC REVIEW
Saarukka LS1, Viljemaa KM1, Backman JT2, Blom M1
1University of Helsinki, Faculty of Pharmacy, Helsinki, Finland, 2University of Helsinki, Faculty of Medicine, Helsinki, Finland

PHP103
D22
PHARMACOECONOMIC ANALYSIS OF DALBAVANCIN USE IN ACUTE BACTERIAL SKIN AND SOFT TISSUE INFECTIONS
Saat-Yerlikaya N1, Yegenoglu S2, Ascioglu S3, Postma MJ4, Atik O5, Sozen-Sahne B2, Unal S6
1Turkish Medicines and Medical Devices Agency, Ankara, Turkey, 2Hacettepe University Faculty of Pharmacy, Ankara, Turkey, 3GlaxoSmithKline, Singapore, Singapore, 4University of Groningen, Groningen, The Netherlands, 5IE Ulagay-Menarini Group, Ankara, Turkey, 6Hacettepe University, Ankara, Turkey

PHP104
D23
COUNTERFACTUAL DECOMPOSITION OF HEALTH CARE EXPENDITURES: FROM COST-BASED PAYMENT TO GLOBAL BUDGET SYSTEM
LIU Y
National Cheng Kung University, Tainan, Taiwan

PHP105
D24
COST-OF-ILLNESS ANALYSIS FOR LYMPHOEDEMA IN A REGIONAL HOSPITAL IN EAST BOHEMIA
Švandová I, Sýkorová/Málková V
Czech Technical University in Prague, Kladno, Czech Republic

PHP106
D25
ANALYSIS OF FINANCIAL STATUS AND THE INVESTMENT STRATEGY OF NATIONAL HOSPITAL ORGANIZATION (NHO) IN JAPAN FROM 2004 TO 2015.
Nakagawa Y1, Tomita N2, Irisa K1, Nakagawa Y1
1National Hospital Organization Shikoku Medical Center for Children and Adults, Zentuji city, Japan, 2National Institute of Public Health, Saitama, Japan

PHP107
D26
EXPLORING DISINVESTMENT DESICIONS IN THE NHS VIA HEALTH ECONOMICS
Lyris N1, Das DP2
1London School of Economics and Political Science (LSE), London, UK, 2Boehringer Ingelheim Limited, Bracknell, UK

PHP108
D27
COST-EFFECTIVENESS ANALYSIS OF INVASIVE FUNGAL INFECTIONS THERAPIES IN FEBRILE NEUTROPENIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES IN THE TURKISH CONTEXT
Atik O1, Yegenoglu S2, Ascioglu S3, Postma MJ4, Saat-Yerlikaya N5, Sozen-Sahne B2, Unal S6
1IE Ulagay-Menarini Group, Ankara, Turkey, 2Hacettepe University Faculty of Pharmacy, Ankara, Turkey, 3GlaxoSmithKline, Singapore, Singapore, 4University of Groningen, Groningen, The Netherlands, 5Turkish Medicines and Medical Devices Agency, Ankara, Turkey, 6Hacettepe University, Ankara, Turkey

PHP109
E1
ASSESSING UPTAKE OF MEDICINE USE REVIEWS IN ENGLISH COMMUNITY PHARMACIES
El-Ghannam M, Stanway VE, Murphy EM
Cogora, London, UK

PHP110
E2
LIVING WITH CHRONIC DISEASES IN GREECE: INVESTIGATING HEALTH SERVICES UTILIZATION PATTERNS AND ECONOMIC CONSEQUENCES
Siati G1, Monokrousou M2, Siskou O3, Konstantakopoulou O4, Galanis P3, Kaitelidou D3, Theodorou M5
1Technological Educadional Institute of Epirus, Arta, Greece, 2Municipality of Pilea- Hortiatis, Pilea-Hortiatis, Greece, 3Center for Health Services Management and Evaluation, National and Kapodistrian University of Athens-Greece/Open University of Cyprus, Latsia, Cyprus, 4Center for Health Services Management and Evaluation, National and Kapodistrian University of Athens, Athens, Greece, 5Open University of Cyprus, Latsia, Nicosia, Cyprus

PHP111
E3
THE INTRODUCTION OF A THRESHOLD FOR THE ICER AND THE IMPLICATIONS FOR REIMBURSEMENT OF DRUGS IN THE DUTCH HEALTHCARE SYSTEM
Karpenko AW1, Geenen JW2, Vreman RA2, Hovels A2
1Utrecht University, UTRECHT, The Netherlands, 2Utrecht University, Utrecht, The Netherlands

PHP112
WITHDRAWN

PHP113
E4
WILL IT BLEND? INCORPORATION OF IRP WITHIN HTA SYSTEMS
Chowdhury CA1, Gambari J2
1CBPartners, New York, NY, USA, 2CBPartners, Singapore, Singapore

PHP114
E5
WILLINGNESS TO PAY FOR QALY IN THE CZECH REPUBLIC BETWEEN 2013 AND 2017: A REVIEW
Vocelka M, Haluska M, Mazel T, Lukacisinova A, Stefancikova I
State Institute for Drug Control, Prague, Czech Republic

PHP115
E6
COULD HEALTHCOIN BE A REVOLUTION IN HEALTHCARE?
Hanna E1, Remuzat C2, Auquier P1, Dussart C3, Toumi M1
1Aix-Marseille University, Marseille, France, 2Creativ-Ceutical, Paris, France, 3Lyon 1 University, Lyon, France

PHP116
E7
AGING OF HEALTH CARE PROFESSIONALS IN HUNGARY
Elmer D, Boncz I, Endrei D, Molics B, Németh N, Kerner Á, Ágoston I
University of Pécs, Pécs, Hungary

PHP117
E8
THE ATTITUDE OF POLISH PHYSICIANS TOWARDS INTRODUCTION OF E-PRESCRIPTION – A QUESTIONNAIRE SURVEY
Kowalczyk M, Hermanowski TR, Kolasa K
Medical University of Warsaw, Warsaw, Poland

PHP118
E9
IMPACT OF WEIGHT CHANGE AFTER QUITTING CIGARETTES ON ALL-CAUSE AND CAUSE-SPECFICIC MORTALITY IN MIDDLE-AGED MALE SMOKERS: NATIONAL HEALTH SCREENING COHORT STUDY
Kim K1, Choi S1, Cho MH2, Jun JH3, Koo HY3, Chang J1, Kim SM1, Lee K3, Park SM1
1Seoul National University, Seoul, Korea, Republic of (South), 2Seoul National University Hospital, Seoul, Korea, Republic of (South), 3Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of (South)

PHP119
E10
EVALUATION OF AN ATTITUDES TOWARD MEDICAL ERRORS SCALE IN PHARMACY AND HEALTHCARE PROFESSIONAL STUDENTS
Griggs S
St Louis College of Pharmacy, St Louis, MO, USA

PHP120
E11
INTERCONTINENTAL LINKS AMONG HEALTH TECHNOLOGY ASSESSMENT ORGANIZATIONS
Cinaroglu S1, Baser O2
1Hacettepe University, Ankara, Turkey, 2Columbia University and STATinMED Research, New York, NY, USA

PHP121
E12
PHARMACEUTICAL CARE WORKLOAD AND WORKFORCE REQUIREMENT AT MINISTRY OF HEALTH PRIMARY CARE CENTERS DURING TEN YEARS MASS GATHERING HAJJ (2006-2015) IN MAKAH REGIONS, SAUDI ARABIA
Alomi YA1, Khayat NA2, Al-Hennawi KI1
1Ministry of Health, RIYADH, Saudi Arabia, 2Makkah Medical Affairs, RIYADH, Saudi Arabia

PHP122
E13
LANDSCAPE OF REPORTED DRUG SHORTAGES IN EUROPEAN COUNTRIES
De Weerdt E, Schaerlaeken S, Simoens S, Casteels M, Huys I
KU Leuven, Leuven, Belgium

PHP123
E14
PHARMACY WORKLOAD AND WORKFORCE REQUIREMENT AT MINISTRY OF HEALTH HOSPITALS DURING TEN YEARS MASS GATHERING HAJJ (2006-2015) IN MAKAH REGION, SAUDI ARABIA
Alomi YA1, Khayat NA2, Alhannawi K1
1Ministry of Health, RIYADH, Saudi Arabia, 2Makkah Medical Affairs, RIYADH, Saudi Arabia

PHP124
E15
HEALTH TECHNOLOGY ASSESSMENT TO IMPROVE PATIENT CARE THROUGH PHARMACEUTICAL CARE: CLINICAL PHARMACIST’S PERSPECTIVE
Kanneganti S
Aster Ramesh Hospital, Guntur, India

PHP125
E16
IMPORTANCE OF TENDERING AFTER PATENT EXPIRY IN GERMANY
Fink C, Ecker C
Ecker + Ecker GmbH, Hamburg, Germany

PHP126
E17
THE DEVELOPMENT OF ACUTE AND CHRONIC INPATIENT BED CAPACITIES IN NEUROLOGICAL, NEUROSURGICAL AND PSYCHIATRIC PROFESSIONS BETWEEN 2002 AND 2016 IN HUNGARY
Ágoston I, Endrei D, Molics B, Szarka E, Elmer D, Gyuró M, Sebestyén A, Boncz I
University of Pécs, Pécs, Hungary

PHP127
E18
MANAGEMENT OF HEALTHCARE PRIORITIES BY SINGLE NATURAL RESOURCE DRIVEN ECONOMIES IN EMERGING MARKETS DURING COMMODITY PRICE FLUCTUATIONS
Egbo D1, Chowdhury CA2, Duttagupta S2
1CBPartners, London, UK, 2CBPartners, New York, NY, USA

PHP128
E19
CLINICAL PHARMACY SERVICES AND WORKFORCE REQUIREMENTS AT MINISTRY OF HEALTH HOSPITALS DURING TEN YEARS MASS GATHERING HAJJ (2006-2015) IN MAKAH AND AL-MEDINA REGIONS, SAUDI ARABIA
Alomi YA1, Khayat NA2, Al-Hennawi KI1
1Ministry of Health, RIYADH, Saudi Arabia, 2Makkah Medical Affairs, RIYADH, Saudi Arabia

PHP129
E20
DEVELOPMENT OF AN SPECIFIC EVALUATION FRAMEWORK FOR ORPHAN DRUGS BASED ON MULTI-CRITERIA DECISION ANALYSIS (MCDA) FOR HEALTH CARE DECISION MAKING IN CATALONIA
Badia X1, Pontes C2, Fontanet M3, Obach M2, Vallano A2, Torrent J2, Guarga L1
1Omakase Consulting, Barcelona, Spain, 2CatSalut, Barcelona, Spain, 3Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

PHP130
E21
EVALUATION OF BRANDING IMPACT ON IRANIAN PHARMACEUTICAL MARKET: A QUALITATIVE STUDY
Kamyabi A1, Zaboli P2, Kebriaeezadeh A3, Saeedi M1, Morteza-Semnani K1, Akbari J1, Rohani E4
1Mazandaran Univeristy of Medical Sciences, Sari, Iran (Islamic Republic of), 2Department of Pharmacoeconomics and Pharmaceutical Management, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran (Islamic Republic of), 3Pharmaceutical Management and Economics Research Cente, Tehran, Iran (Islamic Republic of), 4Tehran University of Medical Sciences, Tehran, Iran (Islamic Republic of)

PHP131
E22
WITHDRAWN

PHP132
E23
THERAPEUTIC REFERENCE PRICING SYSTEM COST-SAVING ABILITY AND ITS IMPACT ON PATIENT OUT-OF-POCKET EXPENSES IN SLOVENIA
Mardetko N, Kos M
University of Ljubljana, Faculty of Pharmacy, Ljubljana, Slovenia

PHP133
E24
PHARMACOECONOMIC RESULTS OF HIGHLY INNOVATIVE DRUGS APPROVED FOR TEMPORARY REIMBURSEMENT IN THE CZECH REPUBLIC
Ornstova E, Sebestianova M, Mlcoch T, Lamblova K, Dolezal T
VALUE OUTCOMES, Prague, Czech Republic

PHP134
WITHDRAWN

PHP135
E25
KEY FACTORS RESULTING IN DIFFERENTIAL REIMBURSEMENT DECISIONS BETWEEN THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) AND THE SCOTTISH MEDICINES CONSORTIUM (SMC) FOR MEDICINES AUTHORISED BY THE EUROPEAN MEDICINES AGENCY (EMA) TO TREAT RARE DISEASES (ORPHAN MEDICINES)
Aguiar-Ibáñez R, Paul E, O'Regan C
Merck Sharp & Dohme UK, Hoddesdon, UK

PHP136
E26
PUBLIC FUNDING OF CANCER TREATMENT: CHANGES TO THE PROCESS AND SUCCESS RATE OVER TIME IN AUSTRALIA
O'Leary BA1, Gordois AL1, Quadri H1, McElroy HJ2
1Covance Market Access Services Inc., Sydney, Australia, 2Covance (Asia) Pte Ltd., Singapore, Singapore

PHP137
E27
WITHDRAWN

PHP138
F1
THE ANALYSIS OF NEW DRUG REIMBURSEMENT DECISION MAKING IN SOUTH KOREA AFTER THE INTRODUCTION OF POSITIVE LISTING SYSTEM
Kim S1, Cho H1, Yoo H2, Cho J3, Kang K4, Kim J5
1Novartis Korea, Seoul, Korea, Republic of (South), 2AstraZeneca Korea, Seoul, Korea, Republic of (South), 3Lilly Korea, Seoul, Korea, Republic of (South), 4Abbvie Korea, Seoul, Korea, Republic of (South), 5Ipsen Korea, Seoul, Korea, Republic of (South)

PHP139
F2
2017 BLACK BOX AMNOG REBATES: WHAT IS DRIVING THE REBATES?
Freiberg M, Schwarz R
Quintiles Commercial Germany GmbH, Mannheim, Germany

PHP140
F3
THE IMPACT OF MODIFYING FACTORS ON ICER FOR PHARMACEUTICAL REIMBURSEMENT RECOMMENDATIONS IN KOREA OVER 10 YEARS
Kim HJ, Jang J, Lee SM, Jung Y, Yoon N, Kim TK, Hwang EJ, Kim K
HIRA (Health Insurance Review & Assessment Service), Gangwon-do, Korea, Republic of (South)

PHP141
F4
DRUG COMMERCIALIZATION BEFORE THE PRICING AND REIMBURSEMENT IN ITALY: THE NON NEGOTIATED C CLASS (C-NN)
Tettamanti A, Cioni L, Mantuano M
QuintilesIMS, Milano, Italy

PHP142
F5
COVERAGE-WITH-EVIDENCE-DEVELOPMENT (CED) IN GERMANY: STATUS QUO
Molnar S, Kreis J, Angelescu K, Sauerland S
Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany

PHP143
F6
DRUG COST CONTAINMENT AND NEGOTIATION POWER
Wiest I1, Obermann K1, Thielscher C2
1MIPH, Mannheim, Germany, 2DKFZ, Heidelberg, Germany

PHP144
F7
ARE P&R OFFICIAL CRITERIA RELATED WITH REAL P&R APPROVAL OF ORPHAN DRUGS (ODS) IN SPAIN?
Badia X, Gil A, Shepherd J, Guarga L
Omakase Consulting, Barcelona, Spain

PHP145
F8
COST-EFFECTIVENESS AND IMPACT OF NEW INNOVATIVE TREATMENTS ON PROGNOSIS OF MELANOMA AND OVARIAN CANCER FOR AUSTRALIAN PATIENTS
Schneider KB1, McElroy HJ2, Lee CK3, O'Leary BA3
1Covance Market Access Services, Inc., Leeds, UK, 2Covance (Asia) Pte Ltd., Singapore, Singapore, 3Covance Market Access Services Inc., Sydney, Australia

PHP146
F9
EXTERNAL REFERENCE PRICING IN GREECE. A COMPARATIVE ANALYSIS FOR 2015-2017
Dede Z1, Manias NG2
1Pricing Committee, ATHENS, Greece, 2MINTE, Athens, Greece

PHP147
F10
MARKET ACCESS TRENDS ACROSS THE EU5: 2009 TO 2016- AN UPDATE
Mycka J1, Dellamano R2, Lobb W1, Dalal N1, Dellamano L2, Pereira E1, Mora M1
1Medical Marketing Economics LLC (MME), Montclair, NJ, USA, 2ValueVector, Milan, Italy

PHP148
F11
NON-QUANTIFIABLE BENEFIT WITHIN THE GERMAN AMNOG SYSTEM: FACTORS CONTRIBUTING TO TIME LIMITS SET FOR BENEFIT RESOLUTIONS AND POTENTIAL IMPLICATIONS ON PRICE DISCOUNTS
Beckert U, Vorwerk H, Löpmeier J, Kulp W
Xcenda GmbH, Hannover, Germany

PHP149
F12
IMPACT OF MULTI-DRUG RESISTANCE ON HTA ASSESSMENT OF ANTIBIOTICS IN FRANCE, GERMANY, UNITED KINGDOM
Charafi N, Chen X
Pope Woodhead, St Ives, UK

PHP150
F13
UNDERSTANDING HEALTH TECHNOLOGY ASSESSMENT OUTCOMES FOR PRODUCTS WITH CONDITIONAL MARKET AUTHORISATION IN FRANCE: INITIAL EVALUATION VS. RE-ASSESSMENT
Ferreira de Alencar E1, Chen X2
1Pope woodhead and Associates, Cambridgeshire, UK, 2Pope Woodhead, St Ives, UK

PHP151
F14
THE ANALYSIS OF FINAL AND SURROGATE EFFECTIVENESS CRITERIA USED IN HEALTH ECONOMIC STUDIES OF DRUGS SUBMITTED INTO THE REIMBURSEMENT IN RUSSIA IN 2016.
Kolbin A1, Omelianovskiy VV2, Kurylev A1
1First Pavlov State Medical University of St. Petersburg, Saint Petersburg, Russia, 2Centre of HTA, Moscow, Russia

PHP152
F15
10 YEARS OF REIMBURSEMENT DECISIONS IN THE NETHERLANDS: AN OVERVIEW
Dvortsin E1, Novak A2, Postma MJ3
1University of Groningen / Asc Academics, Groningen, The Netherlands, 2Anovak Services, Apeldoorn, The Netherlands, 3University of Groningen, Groningen, The Netherlands

PHP153
F16
COMPARISON OF PREVIOUS IPHA-HSE AGREEMENT EFFECTS ON THE HTA ASSESSMENT PROCESS IN IRELAND (2009 – 2016)
Gouldson M, Crossan CJ, Mahon S
BresMed Ireland, Dublin 24, Ireland

PHP154
F17
AN ANALYSIS OF HTA AND REIMBURSEMENT PROCESSES IN EUNETHTA PARTNER COUNTRIES: IMPLICATIONS FOR IMPLEMENTING HTA COOPERATION
Garrett Z
National Institute for Health and Care Excellence (NICE), Manchester, UK

PHP155
F18
IN WHAT SEQUENCE DO COMPANIES SUBMIT HEALTH TECHNOLOGY APPRAISAL (HTA) DOSSIERS IN THE UK AND IRELAND, AND IN WHAT SEQUENCE ARE THEY PUBLISHED?
Norman DL, Marshall JD
MAP BioPharma Limited, Cambridge, UK

PHP156
F19
A TREND TOWARDS INCREASED USE OF PATIENT ACCESS SCHEMES (PAS) TO GAIN UK REIMBURSEMENT
Norman DL, Marshall JD
MAP BioPharma Limited, Cambridge, UK

PHP157
F20
CENTRALIZATION AND COMPLEXITY OF DRUG MARKET ACCESS PROCESS ACROSS ITALIAN REGIONS
Urbinati D, Cioni L, Tucci C
QuintilesIMS, Milano, Italy

HEALTH CARE USE & POLICY STUDIES - Health Care Research & Education
PHP158
F21
SUSPECTED ADVERSE REACTIONS (SARS) TO SYSTEMIC GLUCOCORTICOID USAGE IN DOGS IN PRIMARY VETERINARY PRACTICE IN THE UK
Elkholly D1, O'Neill D1, Mwacalimba KK2, Wright AK2, Church D1, Brodbelt D1, Penny CD3
1Royal Veterinary College, London, UK, 2Zoetis, Indianapolis, IN, USA, 3Zoetis UK, Tadworth, UK

PHP159
F22
EVALUATING THE CONCEPTUAL EQUIVALENCE BETWEEN PAPER AND THREE ELECTRONIC DATA COLLECTION MODES OF THE EQ-5D-5L HEALTH STATUS INSTRUMENT
Crescioni M1, Flood E2, Lundy J3, Coons SJ1, Byrom B4, Eremenco S1
1Critical Path Institute, Tucson, AZ, USA, 2ICON Clinical Research, Gaithersburg, MD, USA, 3Outcometrix, Tucson, AZ, USA, 4ICON Clinical Research, Marlow, UK

PHP160
F23
COMORBIDITY INDICES BASED ON HEALTH-RELATED QUALITY OF LIFE ARE MORE STRONGLY ASSOCIATED WITH PATIENT OUTCOMES THAN MORTALITY-BASED INDICES
Rendas-Baum R, Rizio AA, Bjorner JB
Optum Patient Insights, Johnston, RI, USA

PHP161
F24
RASCH MEASUREMENT ANALYSIS OF THE LOWER EXTREMITY FUNCTIONAL SCALE FOR FOOT AND ANKLE PATIENTS
Repo JP1, Tukiainen EJ1, Roine RP2, Sampo M3, Häkkinen A4
1University of Helsinki and Helsinki University Hospital, Helsinki, Finland, 2Helsinki University Hospital and University of Eastern Finland, Helsinki, Finland, 3Helsinki University Central Hospital, Helsinki, Finland, 4Department of Education and Science, Central Finland Health Care District, Jyväskylä, Finland, Jyväskylä, Finland

PHP162
F25
THE APPLICATION OF BIG DATA ANALYSIS TO MEASURE AND BETTER UNDERSTAND MEDICATION ADHERENCE: A SYSTEMATIC LITERATURE REVIEW.
Pirri S, Turchetti G
Scuola Superiore Sant'Anna, Pisa, Italy

PHP163
F26
EFFECTIVENESS OF OSTEOPOROSIS DRUGS IN PREVENTING SECONDARY HIP FRACTURES IN WOMEN ON DIALYSIS
Lin Y1, Lee T2, Lin M1, Hwang S1, Chen C1, Lin S1
1Kaohsiung Medical University, Kaohsiung, Taiwan, 2Kaohsiung Municipal Ta-Tung Hospital,Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan

PHP164
F27
A SYSTEMATIC LITERATURE REVIEW OF THE MEASUREMENT PROPERTIES OF GENERIC UTILITY INSTRUMENTS IN EAST AND SOUTHEAST ASIA
Luo N1, Ong JJ1, Chuang L2
1National University of Singapore, Singapore, Singapore, 2Pharmerit International, Rotterdam, The Netherlands

PHP165
G1
POPULATION HEALTH STATUS BASED ON THE EQ-5D-3L-Y AMONG ADOLESCENTS IN SWEDEN - RESULTS BY SEX, AGE AND SOCIO-ECONOMIC STATUS
Åström M1, Persson C2, Lindén-Boström M2, Burström K1
1Karolinska Institutet Stockholm, Stockholm, Sweden, 2Region Örebro County, Örebro, Sweden

PHP166
WITHDRAWN

PHP167
G2
AGREEMENT BETWEEN PATIENT AND CLINICIAN RATINGS OF DISEASE SEVERITY IN HIDRADENITIS SUPPURATIVA, RHEUMATOID ARTHRITIS, AND CHRONIC PLAQUE PSORIASIS
Foley C, Banderas B, Sen R, Yip C, Dickie G, Lamoureux RE
Adelphi Values USA, Boston, MA, USA

PHP168
G3
PREDICTORS OF ACTIVITY AND PARTICIPATION IN PEOPLE WITH MOTOR NEURONE DISEASE, MULTIPLE SCLEROSIS AND PARKINSON’S DISEASE.
Morley D1, Dummett S1, Churchman D2, Kelly L1, Jenkinson C1
1University of Oxford, Oxford, UK, 2Clinical Outcomes at Oxford University Innovation, Oxford, UK

PHP169
G4
PATIENT-REPORTED OUTCOMES IN LABELS AND PACKAGE LEAFLETS OF DRUGS APPROVED BY THE EUROPEAN MEDICINES AGENCY FROM 2007 TO 2017
Holm SP1, Fuchsberger M1, Bowden G2, Buisson S1
1Excerpta Medica, Amsterdam, The Netherlands, 2Excerpta Medica, London, UK

PHP170
G5
REPELLENT AND LARVICIDAL ACTIVITY OF THAI MEDICINAL PLANTS AGAINST MOSQUITOES: A SYSTEMATIC REVIEW AND META-ANALYSIS
Saokaew S1, Kiatsomboon I1, Piromyaporn M1, Sivasupaporn N1, Pusparajah P2, Chan KG2, Goh BH2, Lee LH2, Phayak T1, Kengkla K1, Wilairat P3, Duangjai A3, Utsintong M4
1University of Phayao, Muang, Phayao, Thailand, 2Monash University Malaysia, Selangor, Malaysia, Malaysia, 3University of Phayao, Muang phayao, Thailand, 4Unit of Excellence on Herbal Medicine, University of Phayao, Phayao, Thailand

PHP171
G6
DO PEOPLE WITH PRIVATE HEALTH INSURANCE ATTACH A HIGHER VALUE TO HEALTH THAN THOSE WITHOUT INSURANCE? RESULTS FROM AN EQ-5D-5L VALUATION STUDY IN THE REPUBLIC OF IRELAND
Hobbins A1, Barry L2, Kelleher D3, Shah K4, Devlin N4, Ramos-Goñi JM5, O'Neill C2
1NUI Galway, Galway, Ireland, 2Queen's University Belfast, Belfast, UK, 3The National University of Ireland, Galway, Galway, Ireland, 4Office of Health Economics, London, UK, 5RTI Health Solutions, Research Triangle Park, NC, USA

PHP172
G7
EVALUATION OF WEARABLE TECHNOLOGY USE IN CLINICIAN OUTCOMES ASSESSMENT STUDIES
Trivedi B1, Cole JC1, Platko JV2
1ZS Associates, Thousand Oaks, CA, USA, 2CRF Health, Plymouth Meeting, PA, USA

PHP173
G8
RELIABILITY TESTING OF THE FINNISH VERSION OF THE NON-TECHNICAL SKILLS SCALE FOR TRAUMA (T-NOTECHS)
Repo JP1, Rosqvist E2, Lauritsalo S1, Paloneva J1
1Central Finland Health Care District, Jyväskylä, Finland, 2Central Finland Health Care District, Jyvaskylä, Finland

PHP174
G9
QUANTIFYING THE RELATIONSHIP BETWEEN HYPERKALAEMIA AND OUTCOMES IN PATIENTS WITH HEART FAILURE OR CHRONIC KIDNEY DISEASE
Bennett H1, Ayoubkhani D1, Evans M2, McEwan P1, Qin L3, Grandy S4, Palaka E5
1Health Economics and Outcomes Research Ltd, Cardiff, UK, 2University Hospital Llandough, Cardiff, UK, 3AstraZeneca, Gaithersburg, MD, USA, 4Astrazeneca Phamaceuticals , LP, Gaithersburg, MD, USA, 5AstraZeneca, Cambridge, UK

PHP175
G10
WILLINGNESS-TO-PAY FOR LIFE-SAVING TREATMENTS IN THAILAND: A DISCRETE CHOICE EXPERIMENT
Nimdet K1, Ngorsuraches S2
1Suratthani Provincial Public Health Office, Surat thani, Thailand, 2South Dakota State University, Brookings, SD, USA

PHP176
G11
DEVELOPMENT OF A MORTALITY RISK PREDICTION TOOL FOR PATIENTS WITH HEART FAILURE OR CHRONIC KIDNEY DISEASE AT RISK OF HYPERKALAEMIA
Bennett H1, McEwan P1, Ayoubkhani D1, Evans M2, Qin L3, Kim K4, Palaka E5
1Health Economics and Outcomes Research Ltd, Cardiff, UK, 2University Hospital Llandough, Cardiff, UK, 3AstraZeneca, Gaithersburg, MD, USA, 4AstraZeneca, Södertälje, Sweden, 5AstraZeneca, Cambridge, UK

PHP177
G12
THE FIRST EQ-5D-5L VALUE SET IN CENTRAL AND EASTERN EUROPE
Golicki D1, Jakubczyk M2, Graczyk K3, Niewada M1
1Department of Clinical & Experimental Pharmacology, Medical University of Warsaw, Warsaw, Poland, 2SGH Warsaw School of Economics, Warsaw, Poland, 3HealthQuest, Warsaw, Poland

PHP178
G13
THE ROLE OF DISABILITY ON EARLY RETIREMENT
Laires PA1, Gouveia M2, Canhão H3, Branco JC4
1Escola Nacional de Saúde Pública. Universidade NOVA de Lisboa, Lisbon, Portugal, 2Católica Lisbon School of Business and Economics, Lisbon, Portugal, 3Sociedade Portuguesa de Reumatologia, Lisboa, Portugal, 4Sociedade Portuguesa de Reumatologia, Lisbon, Portugal

PHP179
G14
RELIABILITY AND VALIDITY OF TWO PROXY VERSIONS OF EQ-5D-5L IN JAPAN
Noto S1, Igarashi A2, Shiroiwa T3, Fukuda T3, Ikeda S4, Moriwaki K5, Saito S6, Shimozuma K7, Ishida H8, Kobayashi M9
1Niigata University of Health and Welfare, Niigata, Japan, 2University of Tokyo, Tokyo, Japan, 3National Institute of Public Health, Wako, Japan, 4International University of Health and Welfare, Ohtawara, Japan, 5Kobe Pharmaceutical University, Kobe, Japan, 6Okayama University, Okayama, Japan, 7Ritsumeikan University, Kusatsu, Japan, 8Yamaguchi University Graduate School of Medicine, Ube, Japan, 9CRECON Medical Assessment Inc., Tokyo, Japan

PHP180
G15
ALLOWING RESPONDENTS TO SKIP ITEMS DURING ELECTRONIC COLLECTION OF PATIENT-REPORTED OUTCOME (PRO) DATA: DOES IT MATTER?
O'Donohoe P1, Eremenco S2, Coons SJ2, Crescioni M2, Arnera V3
1CRF Health, London, UK, 2Critical Path Institute, Tucson, AZ, USA, 3ERT-Geneva, Geneva, Switzerland

PHP181
G16
KNOWLEDGE AND CONFIDENCE OF HEALTHCARE PROVIDERS WORKING AT HOSPITALS ABOUT APPROPRIATE PRESCRIBING FOR GERIATRICS
Akkawi ME, Nik Mohamed MH
International Islamic University Malaysia, Kuantan, Malaysia

PHP182
G17
THE EFFECT OF CHRONIC DISEASES, FINANCIAL HARDSHIP AND PERSONALITY TYPES IN PATIENT'S MEDICATION ADHERENCE
Ibrahim K1, Schommer JC2, Tieger PD3, Tomaszewski DM4, Brown LM4, Morisky DE5
1University of Minnesota, Minneapolis, MN, USA, 2University of Minnesota College of Pharmacy, Minneapolis, MN, USA, 3SpeedReading People, LLC, Hartford, CT, USA, 4Chapman University, Irvine, CA, USA, 5UCLA School of Public Health, Los Angeles, CA, USA

PHP183
G18
WHY DO PEOPLE PARTICIPATE IN HEALTH-RELATED PREFERENCE STUDIES? A DISCRETE-CHOICE EXPERIMENT
Bridges JF, Janssen EM
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

PHP184
G19
BREAKFAST CONSUMPTION AND ASSOCIATED FACTORS AMONG STUDENTS IN OLABISI ONABANJO UNIVERSITY, OGUN STATE, NIGERIA.
Ojieabu CE, Sholeye O, Ojieabu W, Onabajo B
Olabisi Onabanjo University, Sagamu, Nigeria

PHP185
G20
THE ASSOCIATION BETWEEN MULTIMORBIDITY, SOCIOECONOMIC FACTORS, AND MULTIMORBIDITY-RELATED EXCESS HEALTHCARE USE - RESULTS FROM THE 2014 NATIONAL HEALTH INTERVIEW SURVEY
Laires PA, Perelman J
Escola Nacional de Saúde Pública. Universidade NOVA de Lisboa, Lisbon, Portugal

PHP186
G21
THE COMPARISON AMONG DIFFERENT COUNTRIES’ EQ-5D-5L VALUE SETS APPLIED IN CHINESE GENERAL POPULATION
Zhou T1, Yao Y2, Ma A1
1China Pharmaceutical University, Nanjing, China, 2National School of Development, Peking University, Beijing, China

PHP187
G22
PREFERENCES OF THE GENERAL PUBLIC FOR REIMBURSEMENT CRITERIA FOR EXPENSIVE DRUGS: A MULTI CRITERIA DECISION ANALYSIS FOR RITUXIMAB AND BEVACIZUMAB
van Steen C1, Cakar E1, Treur M2, Verbeek NA1, Franken M3
1Erasmus University Rotterdam, Rotterdan, The Netherlands, 2Pharmerit International, Rotterdam, The Netherlands, 3Erasmus University Rotterdam, Rotterdam, The Netherlands

PHP188
G23
COMPARATIVE EFFECTIVENESS AND SAFETY OF MEDICAL ABORTION FOR SECOND-TRIMESTER PREGNANCY TERMINATION: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
Saokaew S1, Suan-ek P1, Khusawangsri C1, Rattanangamkul T1, Netthip J1, Hongsamsibjet S1, Kengkla K2
1University of Phayao, Muang, Phayao, Thailand, 2University of Phayao, muang phayao, Thailand

PHP189
G24
EVALUATING HEALTH IMPACT OF COMMON CHRONIC CONDITIONS ON QUALITY OF LIFE OF EQ-5D-3L IN OLDER CHINESE
Wang P
Fudan University, Shanghai, China

PHP190
G25
COMPENDIUM OF METHODS FOR MEASURING PATIENT PREFERENCES IN MEDICAL TREATMENT
Soekhai V1, Whichello C2, Levitan B3, Veldwijk J4, Hammad T5, Kihlbom U4, van Overbeeke E6, Russo S7, Mohamed A8, Hermann R9, Huys I6, Patadia V10, Juhaeri J10, de Bekker-Grob E2
1Erasmus University Medical Centre, Rotterdam, The Netherlands, 2Erasmus University Rotterdam, Rotterdam, The Netherlands, 3Janssen R&D, Titusville, NJ, USA, 4Uppsala University, Uppsala, Sweden, 5Merck & Co., North Wales, PA, USA, 6KU Leuven, Leuven, Belgium, 7European Institute of Oncology, Milan, Italy, 8Bayer, Whippany, NJ, USA, 9AstraZeneca, Wilmington, DE, USA, 10Sanofi, Bridgewater, NJ, USA

PHP191
G26
MINIMALLY IMPORTANT DIFFERENCE: EMPIRICAL COMPARISON OF ESTIMATION METHODS USING ORTHOPAEDICS AND OTOLARYNGOLOGY
Peterson AC1, Sutherland JM1, Crump RT2, Liu G1, Janjua A1, Wing K1, Penner MJ1, Younger A1
1University of British Columbia, Vancouver, BC, Canada, 2University of Calgary, Calgary, AB, Canada

PHP192
G27
THE FRENCH COMPASSIONATE PROGRAM "TEMPORARY AUTHORIZATION FOR USE" AND THEREAFTER... HOW CAN IT AFFECT DRUG MARKET ACCESS?
Masia C1, Degrassat-Théas A2, Parent de curzon O2, Loubière A2, Paubel P2
1Paris Descartes, Paris, France, 2General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP) ; Faculté of pharmacy, Paris Descartes University, Sorbonne Paris Cité, Paris, France, Paris, France

PHP193
G28
ESTIMATING THE REFERENCE ICER FOR AUSTRALIA AND PUBLIC PERCEPTIONS TOWARD ITS USE
Edney LC, Haji Ali Afzali H, Cheng T, Karnon J
University of Adelaide, Adelaide, Australia

PHP194
G29
PAYING FOR GENE THERAPIES: APPROACHING A SUSTAINABLE SOLUTION
Spark YM1, Sear R2, Hutchings A1
1Dolon, London, UK, 2Dolon Ltd, London, UK

PHP195
G30
VALUING HEALTH AT THE END OF LIFE: AN EXAMINATION OF FRAMING EFFECTS AND STUDY DESIGN CONSIDERATIONS
Shah K
Office of Health Economics, London, UK

PHP196
G31
DO CHANGING ATTITUDES TO DEATH HAVE IMPLICATIONS FOR NATIONAL TARIFFS FOR HEALTH STATES? RESULTS FROM AN EXAMINATION OF ATTITUDES TO EUTHANASIA IN THE REPUBLIC OF IRELAND.
Barry L1, Hobbins A1, Kelleher D1, Shah K2, Devlin N2, Ramos-Goñi JM3, O'Neill C1
1NUI Galway, Galway, Ireland, 2Office of Health Economics, London, UK, 3RTI Health Solutions, Research Triangle Park, NC, USA

PHP197
G32
A SYSTEMATIC REVIEW TO EVALUATE THE ASSOCIATION BETWEEN MEDICATION ADHERENCE AND PERSONALITY TRAITS
Kohli RK
TheraInsight Pvt. Ltd., Bangalore, India

PHP198
G33
PATIENT OUTCOMES IN WALES: THE PROMS, PREMS & EFFECTIVENESS PROGRAMME (PPEP)
Palmer RI, Withers KL, Carolan-Rees G
Cardiff & Vale University Health Board, Cardiff, UK

PHP199
G34
LOCAL PRODUCTION POLICIES IN THE TURKISH PHARMACEUTICAL MARKET
Şentürk A, Tatar M
Polar Health Economics & Policy Consultancy, Ankara, Turkey

PHP200
G35
MEASUREMENT OF MULTIMORBIDITY TO PREDICT ALL-CAUSE MORTALITY IN A NATIONWIDE POPULATION, USING THE FRENCH NATIONAL HEALTH INSURANCE DATABASE (SNIIRAM).
Constantinou P1, Tuppin P2, Pelletier-Fleury N1
1French National Institute of Health and Medical Research (INSERM), Villejuif, France, 2French National Health Insurance (CNAMTS), Paris, France

PHP201
H1
THE PREVALENCE OF CHRONIC HEALTH CONDITIONS AND MULTIMORBIDITY IN THE PORTUGUESE POPULATION - RESULTS FROM THE 2014 NATIONAL HEALTH INTERVIEW SURVEY
Laires PA1, Rocha L2, Perelman J1
1Escola Nacional de Saúde Pública. Universidade NOVA de Lisboa, Lisbon, Portugal, 2NA, Lisbon, Portugal

PHP202
H2
VARIATION IN OPIOID UTILIZATION BY PHYSICIAN SPECIALTY AND PAYER USING A LINKED CLAIMS-EMR DATABASE
Bonafede MM1, Riehle EC1, Palmer LA2
1Truven Health Analytics, an IBM Company, Cambridge, MA, USA, 2Truven Health Analytics, Bethesda, MD, USA

PHP203
H3
A REVIEW OF METHODS FOR ITEM SELECTION IN THE DEVELOPMENT OF A DESCRIPTIVE SYSTEM FOR QUALITY OF LIFE INSTRUMENT
Singh J1, Longworth L2, Coyle D3, Pokhrel S1
1Brunel University London, London, UK, 2PHMR Ltd, London, UK, 3Brunel University London, Lodon, UK

PHP204
H4
ADHRENCE TO ROUTINE MEDICAL SCREENING AMONG HEALTHCARE PROFESSIONALS
Shaheen N1, Hussein M1, Almuflih A2, Muhanna N2, Alsomaie S2
1King Abdullah International Medical Research Center, Riyadh, Saudi Arabia, 2King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia

PHP205
H5
THE ASSOCIATION BETWEEN MULTIMORBIDITY AND SUBJECTIVE HEALTH STATUS: MEDIATING EFFECT OF ACTIVITIES OF DAILY LIVINGS
Byeon J
KOREA UNIVERSITY, Seoul, Korea, Republic of (South)

PHP206
H6
DISPUTE ISSUES ABOUT THE HEALING AND HEALTH PROMOTION OF CHILDREN
Fusz K1, Rohmann R1, Pakai A2, Pusztai D1, Váradyné Horváth Á1, Behul B1, Boncz I1, Oláh A1
1University of Pécs, Pécs, Hungary, 2University of Pécs, Zalaegerszeg, Hungary

PHP207
H7
EQ-5D-5L POPULATION NORMS FOR MOSCOW (RUSSIA): INTERIM ANALYSIS
Holownia M1, Tarbastaev A2, Golicki D1
1Department of Clinical & Experimental Pharmacology, Medical University of Warsaw, Warsaw, Poland, 2State Budgetary Institution of Moscow City "Clinical Trials and Healthcare Technology Assessment Centre of Moscow Department of Healthcare", Moscow, Russian Federation

PHP208
H8
ASSOCIATION OF MULTIPLE CHRONIC CONDITIONS WITH HEALTH-RELATED QUALITY OF LIFE AND PHYSICAL FUNCTIONING
Sura SD1, Goyal RK2, Adhikari D3, Mehta HB4
1University of Houston, Houston, TX, USA, 2RTI Health Solutions, Research Triangle Park, NC, USA, 3Brown University, Providence, RI, USA, 4University of Texas Medical Branch, Galveston, TX, USA

PHP209
H9
EVALUATION OF STRUCTURED EDUCATIONAL INTERVENTION TO COMMUNITY PHARMACISTS TOWARDS ADVERSE DRUG REACTION REPORTING AND MONITORING IN SOUTH INDIAN DISTRICT
M S S, Adepu R
JSS College of Pharmacy, JSS University, Mysuru, INDIA, Mysuru, India

PHP210
H10
WITHDRAWN

PHP211
H11
REPLICATING THE MEDICATION ADHERENCE REASONS SCALE (MAR-SCALE) FACTOR STRUCTURE IN PEOPLE USING DAILY ORALS FOR DEPRESSION, GASTROESOPHAGEAL REFLUX DISEASE, RHEUMATOID ARTHRITIS, AND EPILEPSY
Kudel I1, Goren A1, Unni E2
1Kantar Health, New York, NY, USA, 2Roseman University of Health Sciences, South Jordan, UT, USA

PHP212
H12
THE ATTITUDE OF PARENTS TO NON-MANDATORY VACCINATIONS
Fusz K1, Tóth K1, Pakai A2, Müller Á1, Rozmann N1, Ferenczy M3, Boncz I1, Oláh A1
1University of Pécs, Pécs, Hungary, 2University of Pécs, Zalaegerszeg, Hungary, 3University of Pécs, Szombathely, Hungary

PHP213
H13
KNOWLEDGE AND SATISFACTION OF HEALTH INSURANCE CLIENTS: CROSS-SECTIONAL STUDY OF A TERTIARY HOSPITAL SERVICES IN GHANA
Nsiah-Boateng E1, Barnes G2, Asenso-Boadi F2, Andoh-Adjei F2, Aikins M1
1University of Ghana, Accra, Ghana, 2National Health Insurance Authority, Accra, Ghana

PHP214
H14
INFLUENCE OF DISEASE FAMILIARITY ON IMPLIED TIME PREFERENCES FOR SEIZURE FREQUENCY REDUCTION
Holmes EA, Morrison V, Hughes DA
Bangor University, Bangor, UK

PHP215
H15
STAKEHOLDER PERSPECTIVES ON THE INTEGRATION OF PATIENT PREFERENCES IN THE MEDICAL PRODUCT LIFE CYCLE: A MULTIMETHOD APPROACH
Janssens R1, Huys I2, van Overbeeke E1, Whichello C3, de Bekker-Grob E3, Kübler J4, Harding S5, Juhaeri J6, Levitan B7, Cleemput I8, Russo S9, Schölin Bywall K10, Veldwijk J10
1University of Leuven, Leuven, Belgium, 2KU Leuven, Leuven, Belgium, 3Erasmus University Rotterdam, Rotterdam, The Netherlands, 4QSciCon, Marburg, Germany, 5Takeda Development Centre Europe Ltd., London, UK, 6Sanofi, Bridgewater, NJ, USA, 7Janssen R&D, Titusville, NJ, USA, 8Belgian Health Care Knowledge Institute (KCE), Brussels, Belgium, 9European Institute of Oncology, Milan, Italy, 10Uppsala University, Uppsala, Sweden

PHP216
H16
PATIENTS ACKNOWLEDGE ADAPTATION: THE CASE OF AMPUTEES
Radu X1, Jofre-Bonet M2, Ayton P2, Cubi-Molla P3
1Inventiv Health, London, UK, 2City University of London, London, UK, 3Office of Health Economics, London, UK

PHP217
H17
SURVEY OF NURSES’ KNOWLEDGE ABOUT SURGICAL WOUND CARE AND ITS COMPLICATIONS AND THE KNOWLEDGE OF WOUND DRESSINGS
Ferenczy M1, Bálint B1, Pakai A2, Pusztai D3, Boncz I3, Szabó L3, Váradyné Horváth Á3, Oláh A3
1University of Pécs, Szombathely, Hungary, 2University of Pécs, Zalaegerszeg, Hungary, 3University of Pécs, Pécs, Hungary

PHP218
H18
METODOLOGY TO ASSESS PRICING AND REIMBURESMENT (P&R) POTENTIAL IN CENTRAL AND EUROPEAN (CEE) COUNTRIES
Augustynska J, Skora K, Walczak J
Arcana Institute Ltd, Krakow, Poland

PHP219
H19
PATIENTS ORIENTED ACCESS SCHEME: LEARNING FROM THE SUCCESS OF THE ISRAELI INNOVATIVE SOLUTION FOR THE ESCALATING DRUGS PRICES
Adijes-Toren A, Brammli-Greenberg S
University of Haifa, Haifa, Israel

PHP220
H20
ACCESS GAP TO INNOVATIVE TREATMENTS IN ROMANIA
Chiriac ND, Radu PC, Mazilu MA
Roche Romania Srl, Bucharest, Romania

PHP221
H21
APPLICABILITY OF THE EQ-5D-3L DESCRIPTIVE SYSTEM TO EXPLORE SUBJECTIVE FUTURE HEALTH EXPECTATIONS
Péntek M, Brodszky V, Rencz F, Baji P, Zrubka Z, Gulácsi L
Corvinus University of Budapest, Budapest, Hungary

PHP222
H22
THE IMPACT OF PATIENT PREFERENCE STUDIES IN THE GERMAN HEALTHCARE SYSTEM
Krinke K, Borchert K, Braun S, Mittendorf T
Xcenda GmbH, Hannover, Germany

PHP223
H23
INPATIENT MEDICATION ERRORS AND PHARMACIST INTERVENTION AT MINISTRY OF HEALTH PUBLIC HOSPITAL IN RIYADH, SAUDI ARABIA
Alomi YA1, Al-Shubbar NA2, Lubad NA2
1Ministry of Health, RIYADH, Saudi Arabia, 2King Salman Hospital, RIYADH, Saudi Arabia

PHP224
H24
CONDITIONS AND CONTEXTUAL FACTORS THAT INFLUENCE THE UTILITY AND APPLICATION OF PATIENT PREFERENCE STUDIES: A STUDY COMBINING LITERATURE AND FOCUS GROUPS
van Overbeeke E1, Whichello C2, Janssens R1, de Bekker-Grob E2, Veldwijk J3, Levitan B4, Kübler J5, Russo S6, Schölin Bywall K3, Cleemput I7, Juhaeri J8, Huys I9
1University of Leuven, Leuven, Belgium, 2Erasmus University Rotterdam, Rotterdam, The Netherlands, 3Uppsala University, Uppsala, Sweden, 4Janssen R&D, Titusville, NJ, USA, 5QSciCon, Marburg, Germany, 6European Institute of Oncology, Milan, Italy, 7Belgian Health Care Knowledge Institute (KCE), Brussels, Belgium, 8Sanofi, Bridgewater, NJ, USA, 9KU Leuven, Leuven, Belgium

PHP225
H25
OVERVIEW OF INNOVATIVE MEDICINE SECTOR IN TURKEY
Kockaya G1, Yenilmez FB2, Sharaf A1, Ammar H1
1CarthaGenetics, Pully, Switzerland, 2Akıl Consultancy, London, UK

PHP226
H26
EVALUATION OF PATIENT- (PRO) AND OBSERVER-REPORTED OUTCOMES (OBSRO) MEASURES REGARDING ACCEPTABILITY AND PALATABILITY OF ELTROMBOPAG IN A PEDIATRIC POPULATION
Sully K1, Roy A2, Bennett B1, D'Alessio D2, Beall S3, Singer ST4
1Adelphi Values Ltd, Bollington, Cheshire, UK, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 3Novartis Pharma AG, Basel, Switzerland, 4UCSF Benioff Children's Hospital, Oakland, CA, USA

PHP227
H27
TESTING THE BEACON TOOL WITH HEALTH ECONOMISTS AND CLINICIANS – IS THERE CONSISTENCY IN ITS APPLICATION?
Kenworthy J, Dunlop W, Xia A, Hirst M, Staufer A, Evans S, Forster R, Walker A
Mundipharma International Ltd, Cambridge, UK

PHP228
H28
NATIONAL SURVEY OF MEDICATION SAFETY PRACTICE AT MINISTRY OF HEALTH HOSPITALS DURING MASS GATHERING (HAJJ-2016) IN SAUDI ARABIA
Alomi YA1, Khayat NA2, Bamagaus YA2, Jumah HM2, Alkharouby AM2, Baljoon MJ2
1Ministry of Health, RIYADH, Saudi Arabia, 2Makkah Medical Affairs, RIYADH, Saudi Arabia

PHP229
H29
CURRENT SITUATION AND DEVELOPMENT OF CHRONIC DISEASES IN CHINA
Xu L
Astrazeneca (China), Beijing, China

PHP230
H30
SKIN-BASED TEMPERATURE MEASURING WITH DIFFERENT THERMOMETER TYPES
Rozmann N1, Pakai A2, Szabó L1, Müller Á1, Szunomár S1, Behul B1, Ferenczy M3, Oláh A1
1University of Pécs, Pécs, Hungary, 2University of Pécs, Zalaegerszeg, Hungary, 3University of Pécs, Szombathely, Hungary

PHP231
H31
ATTITUDE OF PHARMACY EDUCATORS TOWARDS COMPLEMENTARY AND ALTERNATIVE MEDICINES (CAM) EDUCATION IN PHARMACY CURRICULUM: A QUALITATIVE EXPLORATION
Farooqui M1, Farooqui MA2, Ismail WI3, Shaukat Ali R4, Gnanasan S5, Karuppannan M5, Othman CN6
1Department of Pharmacy Practice, Unaizah College of Pharmacy, Qassim University, Saudi Arabia, Saudi Arabia, 2Unaizah College if Medicine, Alqassim, Saudi Arabia, Saudi Arabia, 3Faculty of Health Sciences, University Technology MARA, Penang, Malaysia, 4Department of Pharmacy, Hospital Sultan Abdul Halim, Kedah, Malaysia, 5Department of Pharmacy Practice, Faculty of Pharmacy, University Technology MARA, Selangor, Malaysia, 6Universiti Teknologi MARA (UiTM), Kepala Batas, Malaysia

PHP232
H32
PRACTICALITIES OF USING REAL-WORLD EVIDENCE (RWE) IN COMPARATIVE EFFECTIVENESS RESEARCH (CER): LEARNINGS FROM IMI-GETREAL
Makady A1, Stegenga H2, Ciaglia A3, Debray TP4, Lees M5, Ryll B6, Abrams KR7, Thwaites R8, Garner S9, Jonsson P10, Goettsch W11
1The National Healthcare Institute (ZIN), Diemen, The Netherlands, 2National Institute for Health and Care Excellence, London, UK, 3International Alliance of Patients' Organizations, London, UK, 4University Medical Centre Utrecht, Utrecht, The Netherlands, 5Bristol-Myers Squibb, Rueil Malmaison, France, 6Melanoma Patient Network Europe, and Uppsala University (Department EBC), Uppsala, Sweden, 7University of Leicester, Leicester, UK, 8Takeda, London, UK, 9NICE, London, UK, 10National Institute for Health and Care Excellence (NICE), Manchester, UK, 11Utrecht University, UTRECHT, The Netherlands

PHP233
H33
LEADERSHIP IN NURSING
Satayeva L.G.., Kelimchanova S. Mirzabaeva N.A. Parmankulova T. L
Kazakchstan National Medical University name Asfendiarov, Almaty, Kazakhstan

PHP234
H34
COMPETENCIES OF FORMAL CARERS REGARDING BASIC CLINICAL AND SOFT SKILLS IN THE PROVISION OF OUTPATIENT SERVICES AND PATIENTS’ PERSPECTIVE: THE TWO SIDES OF THE SAME COIN
Kaitelidou D1, Baret C2, Konstantakopoulou O1, Zafiropoulou M3, Theodorou M4, Siskou O5, Kalafati M6, Chatzopoulou M6, Karra V6, Delloro G7, Patiraki Ε6, Lemonidou C6, Sourtzi P6
1Center for Health Services Management and Evaluation, National and Kapodistrian University of Athens, Athens, Greece, 2Aix-Marseille Université, Faculté d'économie et de gestion, Laboratoire d'économie et de sociologie du travail – CNRS, Aix-en-Provence, France, 3Hellenic Open University, Patras, Greece, 4Open University of Cyprus, Latsia, Nicosia, Cyprus, 5Center for Health Services Management and Evaluation, National and Kapodistrian University of Athens-Greece/Open University of Cyprus, Latsia, Cyprus, 6National and Kapodistrian University of Athens, Athens, Greece, 7Azienda Speciale Retesalute, Merate LC, Italy

PHP235
H35
COMMUNITY PHARMACISTS' INTEREST IN AND ATTITUDE TO PHARMACY PRACTICE RESEARCH IN ETHIOPIA: A CROSS-SECTIONAL STUDY
Gebreyohannes EA1, Gebresillassie BM2, Bhagavathula AS1, Belay YB3, Tafere CT3, Erku DA1
1University of Gondar, Gondar, Ethiopia, 2university of gondar, gondar, Ethiopia, 3Mekelle University, Mekelle, Ethiopia

PHP236
I1
KNOWLEDGE AND ATTITUDES IDENTIFYING VICTIMS OF HUMAN TRAFFICKING IN THE US: A CROSS-SECTIONAL STUDY
Patel I1, Perez-Rodriguez S2, Eppes D2, Atta E2, Nord L3, Han Y4
1Marshall University, Huntington, VA, USA, 2Shenandoah University, Winchester, VA, USA, 3Marshall University, Huntington, WV, USA, 4University of Michigan, Ann Arbor, MI, USA

PHP237
I2
ASSESSMENT OF KNOWLEDGE AND PERCEIVED PRACTICES OF ANTIMICROBIAL STEWARDSHIP AMONG MALAYSIAN FUTURE HEALTHCARE PROFESSIONALS
Ahmad S1, Sulaiman LH1, Qamar M1, Shaikh FA1, Ismail NE2
1MAHSA University, Bandar Saujana Putra, Malaysia, 2MAHSA University, Bandar Saujana Putra, Jenjarom Kuala Langat, Selangor, Malaysia

HEALTH CARE USE & POLICY STUDIES - Health Technology Assessment Programs
PHP238
I3
THE ROLE OF PATIENT-REPORTED OUTCOMES AND PATIENT ENGAGEMENT IN HEALTH TECHNOLOGY ASSESSMENTS AND REIMBURSEMENT DECISION MAKING IN 10 COUNTRIES
Lee J1, Kitchen H1, Fletcher-Louis M2
1DRG Abacus, Manchester, UK, 2DRG Abacus, London, UK

PHP239
I4
THE USE OF REAL WORLD DATA FOR NICE DECISION-MAKING: A REVIEW OF SUBMISSIONS TO THREE TREATMENT EFFECTIVENESS EVALUATION PROGRAMMES IN 2015 AND 2016
Glen F1, Pulfer A2
1pH Associates, Runcorn, UK, 2pH Associates (an Open Health company), Marlow, UK

PHP240
I5
WHEN THE OUTCOME OF AN APPRAISAL IS NOT NICE: A REVIEW OF NICE APPEALS
O'Day K1, Campbell DJ1, Meyer KL2
1Xcenda, Palm Harbor, FL, USA, 2Xcenda, LLC, Palm Harbor, FL, USA

PHP241
I6
HOW DO NICE EVIDENCE REVIEW GROUPS PERCEIVE SINGLE TECHNOLOGY APPRAISALS PRESENTING LIMITED EVIDENCE OF COMPARATIVE TREATMENT EFFICACY?
Langford BE, Beaver S, Besford M, Castell A, Dierker Viik A, Eddowes LA
Costello Medical Consulting Ltd, Cambridge, UK

PHP242
I7
INDIRECT COMPARISIONS PRESENTED IN GERMAN BENEFIT ASSESSMENTS – STATUS QUO AND QUO VADIS?
Kreisor M, Schiffter-Weinle HA, Boehler Y
TH Koeln, University of Applied Sciences, Leverkusen, Germany

PHP243
I8
A COMPARATIVE REVIEW OF VALUE ASSESSMENT FRAMEWORKS IN GERMANY, FRANCE, ENGLAND, AUSTRALIA, AND SOUTH KOREA: AN INDUSTRY PERSPECTIVE
Campbell PR1, Gaebler JA1, Boylston M1, Michas Z1, Koo BJ1, Funderburk A1, Haninger K2, Grainger D2
1Health Advances, Weston, MA, USA, 2Pharmaceutical Research and Manufacturers of America (PhRMA), Washington, DC, USA

PHP244
I9
EARLY SCIENTIFIC ADVICE AT CADTH – OPTIONS AND RECOMMENDATIONS FOR FUTURE DEVELOPMENT
Husereau D1, Sood AR2
1Institute of Health Economics, Ottawa, ON, Canada, 2Canadian Agency for Drugs and Technologies in Health, Ottawa, ON, Canada

PHP245
I10
HOW WILL PROPOSED CHANGES TO THE NICE HIGHLY SPECIALISED TECHNOLOGY EVALUATION PROCESS IMPACT PATIENT ACCESS TO INNOVATIVE DRUGS FOR RARE DISEASES?
Nicholson L, Fountain DL, Longworth L, Adkins E
PHMR Ltd, London, UK

PHP246
I11
WITHDRAWN

PHP247
I12
WHEN THE PRICE IS RIGHT: WHEN, IN PRACTICE, ARE CONFIDENTIAL DISCOUNTS INTRODUCED IN THE NICE PROCESS?
Noon K1, Ulrich A2, Painter C1, Montgomery S2
1Costello Medical Consulting Ltd, London, UK, 2Costello Medical Consulting Ltd, Cambridge, UK

PHP248
I13
EARLY HTA ADVICE IN EUROPEAN COUNTRIES: SCOPE AND ASSOCIATED COSTS
Palkmets O, Nagda N, Sear R
Dolon Ltd, London, UK

PHP249
I14
ACCEPTANCE OF POPULATION-ADJUSTED INDIRECT TREATMENT COMPARISON METHODS IN NICE ASSESSMENTS
Ivanescu C1, Skaltsa K2, Kráľ P3
1QuintilesIMS, Hoofddorp, The Netherlands, 2QuintilesIMS, Barcelona, Spain, 3QuintilesIMS, Bratislava, Slovakia

PHP250
I15
COMPARISON OF THE REIMBURSEMENT DECISIONS OF PHARMACEUTICALS IN HUNGARY, ROMANIA AND TURKEY
Atikeler K1, Csanadi M2, Subtirelu M3, Baran A4, Daneasa D5, Preda AL6, Petrescu M6, Akyurek CE7
1Turkish Medicines and Medical Devices Agency, Ankara, Turkey, 2University of Pécs, Pécs, Hungary, 3University of Medicine and Pharmacy, Craiova, Romania, 4Akademia Leona Kozminiskiego Utrecht Area, Utrecht, The Netherlands, 5VUB, Free University of Brussels, Belgium, BRUSSELS, Belgium, 6University of Medicine and Pharmacy „Carol Davila”, Bucharest, Romania, 7Ankara University, Ankara, Turkey

PHP251
I16
INITIATIVES THAT IMPACT PRICING AND REIMBURSEMENT OF ORPHAN (AND ULTRA ORPHAN) DRUGS: REVIEW OF EUROPEAN TRENDS
Rousseau B, Poinas A, Oliver L, Collings H
Adelphi Values Ltd, Bollington, UK

PHP252
I17
THE COST-EFFECTIVENESS OF MANUFACTURER FEES FOR HTAS: ARE THEY PROMOTING OR HINDERING INNOVATION?
Wang GD, Macaulay R
PAREXEL International, London, UK

PHP253
I18
DO NICE APPEALS MAKE A DIFFERENCE? IMPACT OF APPEALS ON APPRAISAL OUTCOMES
O'Day K1, Campbell DJ1, Meyer KL2
1Xcenda, Palm Harbor, FL, USA, 2Xcenda, LLC, Palm Harbor, FL, USA

PHP254
I19
CONFIRMATORY VERSUS EXPLORATIVE ENDPOINT ANALYSIS: DECISION-MAKING UNDER UNCERTAINTY ON THE BASIS OF EVIDENCE AVAILABLE FROM MARKET AUTHORIZATION AND EARLY BENEFIT ASSESSMENT IN GERMANY
Niehaus I1, Dintsios C2
1Cologne Institute for Health Economics and Clinical Epidemiology, Cologne, Germany, 2Heinrich Heine University of Düsseldorf, Düsseldorf, Germany

PHP255
I20
ASSESSING CRITERIA FOR NICE RECOMMENDATION WITH THE HST PROGRAMME
Upton CM1, Wordsworth J2, Cork D2, Curry A1, Ralston S1
1SIRIUS Market Access, London, UK, 2SIRIUS Market Access, Newcastle upon Tyne, UK

PHP256
I21
MARKET ACCESS OF ADVANCED THERAPY MEDICINAL PRODUCT (ATMP) IN EUROPE: LESSONS LEARNT AND KEY CONSIDERATIONS FOR FUTURE SUCCESS
Zhang A, Chen X
Pope Woodhead, St Ives, UK

PHP257
I22
AMNOG DOSSIERS AS A CHALLENGE FOR PHARMACEUTICAL COMPANIES: IS THERE A CORRELATION BETWEEN VOLUMES AND ADDED MEDICAL BENEFIT?
Kulp W, Reinartz MT
Xcenda GmbH, Hannover, Germany

PHP258
I23
UTILIZATION AND EVALUATION OF DELPHI PANELS IN GERMAN AMNOG ASSESSMENTS
Kohlscheen KM, Jacob C, Altevers J, Mittendorf T
Xcenda GmbH, Hannover, Germany

PHP259
I24
12 MONTH REVIEW OF NICE AND SMC RECOMMENDATIONS FOR NEW TECHNOLOGIES
Hendrich J, Boodhna T
WG Access, London, UK

PHP260
I25
COMPARATIVE ANALYSIS OF THE DEVELOPMENT OF THE BULGARIAN AND THE ROMANIAN HTA SYSTEM
Trendafilova P1, Benisheva T1, Sidjimova D1, Cherneva D2, Vodenitcharov T2
1Faculty of Public Health Medical University - Sofia, Bulgaria, Sofia, Bulgaria, 2Medical University - Sofia, Sofia, Bulgaria

PHP261
I26
ASSESSMENT OF PUBLIC OPINION REGARDING THE ETHICS OF NICE CDF, HST, AND END-OF-LIFE CRITERIA FOR DRUG REIMBURSEMENT
Upton CM1, Wordsworth J2, Cork D2, Ralston S1
1SIRIUS Market Access, London, UK, 2SIRIUS Market Access, Newcastle upon Tyne, UK

PHP262
I27
AN AUDIT OF EVIDENCE REVIEW GROUP CRITICISMS OF SYSTEMATIC LITERATURE REVIEWS CONDUCTED TO INFORM MANUFACTURERS' SUBMISSIONS TO THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
Leonard S, Summers J, Young E
Costello Medical Consulting Ltd, Cambridge, UK

PHP263
I28
A COMPARISON OF HEALTH TECHNOLOGY ASSESSMENT (HTA) REQUIREMENTS FOR SYSTEMATIC LITERATURE REVIEWS (SLRS)
Sarnes E1, Cadarette SM1, Sawchyn B1, Gittings K1, Kulp W2, Siu EC3, Ruiz K1, Wissinger E1
1Xcenda, L.L.C., Palm Harbor, FL, USA, 2Xcenda GmbH, Hannover, Germany, 3Innomar Strategies, Oakville, ON, Canada

PHP264
I29
THE USE OF MCDA IN HTA DECISION MAKING IN BULGARIA
Sidjimova DA1, Stoimenova A2, Benisheva T3, Borisov B4, Trendafilova P3
1Medical University-Sofia, Sofia, Bulgaria, 2The Bulgarian Drug Agency, Sofia, Bulgaria, 3Faculty of Public Health Medical University - Sofia, Bulgaria, Sofia, Bulgaria, 4Prescriptia Ltd, Sofia, Bulgaria

PHP265
I30
EXTRAPOLATION OF ADULT DATA FOR PEDIATRIC DRUG BENEFIT ASSESSMENT IN THE AMNOG DOSSIER IN THE LIGHT OF THE NEW AMVSG
Stöcker P1, Bonduelle D2, Hofmann-Xu L1
1QuintilesIMS Health, Munich, Germany, 2QuintilesIMS, Munich, Germany

PHP266
I31
DEFINING CRITERIA WEIGHTS BY AHP IN HEALTH TECHNOLOGY ASSESSMENT
Öztürk N1, Karacan I2, Tozan H3, Vayvay Ö1
1Marmara University, Istanbul, Turkey, 2National Defense University Turkish Naval Academy, Istanbul, Turkey, 3Medipol University, Istanbul, Turkey

PHP267
I32
COMPARISON OF EARLY SCIENTIFIC ADVICE PROCESSES IN UK, FRANCE AND GERMANY (HTA ONLY): TIPS AND TRICKS
Vlachaki I1, Ovcinnikova O1, Storck C2, El Mouaddin N3, Shah M4
1Mapi, London, UK, 2Mapi, Munich, Germany, 3Mapi Group, Nanterre, France, 4Mapi, Boston, MA, USA

PHP268
I33
RETROSPECTIVE ANALYSIS OF THE CEESP EFFICIENCY OPINIONS AND ELIGIBILITY CRITERIA FOR ASSESSMENT SINCE ITS CREATION
Chriv E1, Moreau L1, Pacheco L2, Teale CW3
1GfK Market Access, London, UK, 2GfK UK, London, UK, 3GfK UK Limited, Melton Mowbray, UK

PHP269
I34
QUALITY ASSURED USE OF PHARMACEUTICALS: DOES GERMAN GBA FOLLOW EMA?
Menzler J1, Minartz C1, Thienel P2, Neubauer AS1
1Institute for Health- and Pharmaeconomics (IfGPh), Muenchen, Germany, 2Institute for Healtheconomics (IfG), Muenchen, Germany

PHP270
I35
RELATIVE VALUE OF EVIDEM MCDA FRAMEWORK FOR REFLECTIVE DRUG EVALUATION AMONG THERAPEUTIC POSITIONING REPORT EVALUATORS FROM THE SPANISH AGENCY OF MEDICINES
Hernández C1, Blázquez A1, Gil A2, Badia X2
1Spanish Agency of Medicinal Products and Medical Devices (AEMPS), Madrid, Spain, 2Omakase Consulting, Barcelona, Spain

PHP271
J1
MAINTAINING THE BELT AND ROAD – THE IMPACT OF 'BREXIT' ON UK MARKET ACCESS
Wang GD, Macaulay R
PAREXEL International, London, UK

HEALTH CARE USE & POLICY STUDIES - Population Health
PHP272
J2
POSITIVE EXTERNALITIES OF AUSTERITY? THE CASE OF SMOKING CESSATION DURING THE FINANCIAL CRISIS IN GREECE.
Pavi E1, Naoum V1, Athanasakis K2, Kyriopoulos J1
1National School of Public Health, Athens, Greece, 2Open University of Cyprus, Latsia, Nicosia, Greece

PHP273
WITHDRAWN

HEALTH CARE USE & POLICY STUDIES - Prescribing Behavior & Treatment Guidelines
PHP274
J3
DEVELOPMENT OF PHARMACOECONOMIC GUIDELINES IN UKRAINE: METHODOLOGICAL ISSUES AND POLICY IMPLICATIONS
Piniazhko O1, Zalis'ka O1, Nemeth B2
1Danylo Halytsky Lviv National Medical University, Lviv, Ukraine, 2Syreon Research Institute, Budapest, Hungary

PHP275
J4
IMPLEMENTABILITY EVALUATION OF ANTIBIOTICS FOR ABDOMINAL TRAUMA GUIDELINE USING THE GUIDELINE IMPLEMENTABILITY APPRAISAL (GLIA) TOOL
Choi M, Jung Y
National Evidence-based Healthcare Collaborating Agency, Seoul, Korea, Republic of (South)

PHP276
J5
A COMPARISON OF SYSTEMIC PEDIATRIC FLUOROQUINOLONE USE IN SOUTH KOREA
Kwon MJ1, KIM SE1, Song SY2, Kim E3
1Department of Pharmaceutical Industry Management, The Graduate School, Chung-Ang University, Seoul, Korea, Republic of (South), 2Chung-Ang University College of Pharmacy, Seoul, Korea, Republic of (South), 3Evidence-Based Research and Clinical Research Lab., Department of Health, Social and Clinical Pharmacy, College of Pharmacy, Chung-Ang University, Seoul, Korea, Republic of (South)

PHP277
J6
PRIMARY NONADHERENCE: DO DIFFERENCES EXIST BETWEEN LIFE SUSTAINING AND QUALITY OF LIFE MEDICATIONS?
Johnson BH1, Henriques C2, Bonafede MM1
1Truven Health Analytics, an IBM Company, Cambridge, MA, USA, 2Truven Health Analytics, an IBM Company, Ann Arbor, MI, USA

PHP278
J7
EVALUATING PHYSICIANS’ PERCEPTION OF LIMITATIONS AND OBSTACLES AGAINST THE EFFECTIVENESS OF “AUDIT AND FEEDBACK” AND “PRINTED EDUCATIONAL MATERIALS” INTERVENTIONS ON PRESCRIBING BEHAVIOR: A QUALITATIVE STUDY
Soleymani F, Rashidian A, Jaafarbeigi J
Tehran university of medical sciences, Tehran, Iran (Islamic Republic of)

PHP279
J8
THE FIRST FIVE MONTHS OF NATIONAL PRESCRIPTION MONITORING IN FINLAND
Jormanainen VJ1, Lindgren M2
1THL, Helsinki, Finland, 2Kela, Helsinki, Finland

HEALTH CARE USE & POLICY STUDIES - Regulation of Health Care Sector
PHP280
J9
CREATING ORDER IN CHAOS - THE IMPACT OF BREXIT ON THE REGULATORY ENVIRONMENT IN EUROPE AND THE UNITED KINGDOM
Wang GD, Macaulay R
PAREXEL International, London, UK

PHP281
J10
PRICING REGULATION IN GREECE - ANALYZING THE PRICE BULLETIN OF DECEMBER 2016
Papadopoulos K, Stefanidou Z, Pentafragka E, Ollandezos M
Panhellenic Association of Pharmaceutical Industry, Athens, Greece

PHP282
J11
CHARACTERISTICS AND APPROVALS OF REGULATORY SUBMISSIONS BASED ON NON-RANDOMIZED STUDIES IN THE UNITED STATES AND EUROPE
Goring SM1, Taylor A2, Mueller K1, Li JJ1, Waser N1, Levy A3, Freemantle N4
1ICON plc., Vancouver, BC, Canada, 2Takeda Development Centre Europe, London, UK, 3Dalhousie University, Halifax, NS, Canada, 4University College London, London, UK

PHP283
J12
THE SUCCESS OF EU OMP LEGISLATION: AN EMPIRICAL ANALYSIS
Sola-Morales O
HiTT, Barcelona, Spain

PHP284
J13
THE ANALYSIS OF THE RELATION BETWEEN THE DURATION OF ADMINISTRATIVE PROCEDURES AND THE METHODOLOGICAL ACCURACY AND REVIEWABILITY AS WELL AS THE RESULTS OF THE SUBMITTED PHARMACOECONOMIC ANALYSES
Zizalova J, Rrahmaniova D, Vrubel F, Davidova T
Ambruz & Dark Deloitte Legal, Prague 8, Czech Republic

HEALTH CARE USE & POLICY STUDIES - Risk Sharing/Performance-Based Agreements
PHP285
J14
WITHDRAWN

PHP286
J15
COVERAGE EVIDENCE DEVELOPMENT IN THE COURSE OF THE DRUG REEVALUATION IN KOREA
Na Y
HIRA (Health Insurance Review & Assessment Service), Wonju-si, Gangwon-do, Korea, Republic of (South)

PHP287
J16
ADVANCED THERAPY MEDICINAL PRODUCTS – TRANSFORMATIONAL PATIENT BENEFITS BUT DESTINED FOR COMMERCIAL FAILURE?
Macaulay R
PAREXEL International, London, UK

PHP288
J17
DEVELOPING A MULTI-CRITERIA FRAMEWORK FOR INNOVATION AND BIOLOGIC DRUGS ASSESSMENT DECISION MAKING IN EGYPT
Fouad S1, ElMordy B2
1Pharmacoeconomic Unit, Central Administration for Pharmaceutical Affairs, Ministry of Health, Egypt, Cairo, Egypt, 2Pricing department, Central Administration for Pharmaceutical Affairs, Ministry of Health, Egypt, Cairo, Egypt

PHP289
J18
IMPLEMENTING MANAGED ENTRY AGREEMENTS IN PRACTICE: THE DUTCH REALITY CHECK
Makady A1, van Veelen A2, de Boer A2, Hillege JL3, Klungel O2, Goettsch W1
1The National Healthcare Institute (ZIN), Diemen, The Netherlands, 2Utrecht University, Utrecht, The Netherlands, 3University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

PHP290
J19
IDENTIFICATION OF ASSESSMENT AND FUNDING MODELS APPLICABLE TO COMPANION DIAGNOSTICS IN UK, FRANCE AND GERMANY
Zegaoui Y1, Pacheco L2, Teale CW3
1GfK UK Limited, London, UK, 2GfK UK, London, UK, 3GfK UK Limited, Melton Mowbray, UK

PHP291
J20
ANALYSIS OF DRUG UTILISATION DATA SOURCES TO ENABLE NATIONWIDE VALUE-BASED PRICING OF MEDICINES ACROSS HEALTHCARE SYSTEMS IN EUROPE
Menner J, Jimenez Ruiz Md, Lewandowska PK
F. Hoffmann-La Roche, Basel, Switzerland

PHP292
J21
THE IMPACT OF MANAGED ENTRY AGREEMENTS ON DRUG TIME TO MARKET IN ITALY
Urbinati D, Rova A, Mantuano M
QuintilesIMS, Milano, Italy

PHP293
J22
THE EFFECT OF VALUE BASED INSURANCE DESIGNS ON COSTS: A SYSTEMATIC REVIEW
Krack G
Ludwig Maximilians University Munich, München, Germany

PHP294
J23
REIMBURSED DRUGS WITH ALTERNATIVE PAYMENT MODEL IN TURKEY
Demir O1, Şentürk A2, Kahveci R3
1Boehringer Ingelheim Tic A.S., Istanbul, Turkey, 2Polar Health Economics & Policy Consultancy, Ankara, Turkey, 3Ankara Numune Training and Research Hospital, Ankara, Turkey

PHP295
J24
LESSONS LEARNED WITH MANAGED ENTRY AGREEMENTS IN PORTUGAL
Gonçalves L, Caldeira S, Teixeira M
INFARMED, I.P., Lisbon, Portugal

HEALTH CARE USE & POLICY STUDIES - Conceptual Papers
PHP296
J25
ASSESSMENT AND COMPARISON OF NATIONAL AND INTERNATIONAL REGULATIONS ON REGISTRATION OF BIOSIMILARS
Tuna E, Sahin S
Hacettepe University, Ankara, Turkey

PHP297
J26
THE IMPLICATIONS OF BREXIT ON THE UK NHS AND THE UK PHARMACEUTICAL INDUSTRY
Sattar S, Hughes T, Marshall JD
MAP BioPharma Limited, Cambridge, UK

PHP298
J27
AN INNOVATIVE SOLUTION TO ACHIEVE COST-EFFECTIVENESS AND A POSITIVE NICE APPRAISAL? – THE CABAZITAXEL CASE STUDY
Macaulay R1, Dave K1, Walsh SC2
1PAREXEL International, London, UK, 2PAREXEL, London, UK

PHP299
J28
MANAGED ACCESS AGREEMENTS (MAAS) IN APPRAISALS CONDUCTED BY THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE)
Balman E, Marshall JD
MAP BioPharma Limited, Cambridge, UK

PHP300
J29
PAYERS, POLITICS AND PANDEMONIUM: AN INSIGHT INTO THE FUTURE UK PRICING AND MARKET ACCESS ENVIRONMENT
Spoors J1, Kusel J2
1RJW & Partners, London, UK, 2Costello Medical Consulting Ltd., London, UK

PHP301
J30
AFFORDABILITY AND WTP CHALLENGES OF COMBINATIONS OF HIGH VALUE/HIGH PRICED PRODUCTS IN ONCOLOGY – IDENTIFYING SOLUTIONS FOR IMMUNOTHERAPIES, PRECISION MEDICINES, AND ANTI-BODY DRUG CONJUGATES
Teale CW1, Fitzgerald TA2
1GfK UK Limited, Melton Mowbray, UK, 2GfK, Melton Mowbray, UK

PHP302
J31
SHOULDN’T NICE COST-EFFECTIVENESS THRESHOLDS BE CHANGING WITH THE TIMES?
Boodhna T, Hendrich J
WG Access, London, UK

PHP303
J32
ARE PATIENT OUTCOMES BEING RELEGATED BY NICES BUDGET IMPACT TEST?
Boodhna T, Hendrich J
WG Access, London, UK

PHP304
J33
CHALLENGES AND FUTURE PERSPECTIVES ON THE REIMBURSEMENT OF ADVANCED THERAPY MEDICINAL PRODUCTS
Rothwell S1, January D2, Duda M3, Gardner K1, Michel S1
1Evidera, London, UK, 2Evidera, Bethesda, MD, USA, 3Evidera, San Francisco, CA, USA

PHP305
J34
WITHDRAWN

PHP306
J35
TISSUE/SITE AGNOSTIC REGULATORY APPROVAL OF ONCOLOGY DRUGS: ARE HTAS READY FOR A NEW ERA IN PERSONALISED MEDICINE?
Sammon C, Mbanya Z, Sen Nikitas F
PHMR Ltd, London, UK

PHP307
K1
AN ANALYSIS OF THE CURRENT JORDANIAN PRICING SYSTEM AND DEVELOPING RECOMMENDATIONS FOR ITS ENHANCEMNET
Batarseh S1, El Khoury AC2, Ashraf RM3
1Jordan food and Drug Association, Amman, Jordan, 2Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 3University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, AR, USA

PHP308
K2
EFFECT OF HEALTH SYSTEM, FINANCING, AND MACRO-ECONOMIC CHARACTERISTICS ON THE MIGRATION OF FOREIGN PHYSICIANS TO OECD COUNTRIES
Aydin S
University of South Carolina, Columbia, SC, USA

PHP309
K3
VALUE ADDED MEDICINES: ADJUSTEMENTS OF HTA DECISION FRAMEWORKS TO CAPTURE THEIR FULL VALUE
Rémuzat C1, Toumi M2
1Creativ-Ceutical, Paris, France, 2Aix-Marseille University, Marseille, France

PHP310
K4
ESTIMATION OF PREVALENCE IN RARE DISEASE
Irwin J1, Auvin S2, Abi-Aad P3, Gibson E3, Battersby A3
1Zogenix International Limited, Maidenhead, UK, 2Université Paris Diderot, Paris, France, 3Wickenstones Ltd, Oxfordshire, UK

PHP311
K5
A HEALTHCARE POLICY STUDY TO BUILD A ROADMAP FOR RARE DISEASE MANAGEMENT UNDER THE EGYPTIAN HEALTHCARE SYSTEM
Soliman NA1, Sallam R2, Anan I2
1Cairo University, Cairo, Egypt, 2Accsight, Cairo, Egypt

PHP312
K6
WITHDRAWN

PHP313
K7
SPECIFICITIES OF CANCER IMMUNOTHERAPY – CHALLENGES FROM MARKET ACCESS PERSPECTIVE
Lach K1, Chouaid C2, Rémuzat C3, Toumi M4
1Creativ-Ceutical, Krakow, Poland, 2Centre Hospitalier Intercommunal, DHU-ATVB, Département de Pneumologie et Pathologie Professionnelle, Créteil, France, 3Creativ-Ceutical, Paris, France, 4Aix-Marseille University, Marseille, France

PHP314
K8
WILL 2017 UPDATES TO THE HIGHLY SPECIALISED TECHNOLOGIES PROGRAMME BENEFIT OR HARM VULNERABLE PATIENTS?
Boodhna T, Hendrich J
WG Access, London, UK

PHP315
K9
BUT WILL THEY TRADE HEALTH? DEVELOPING AN ECONOMIC VALUE FRAMEWORK FOR ONCOLOGY
Briggs A1, Baba C1, Lipitz-Snyderman A2, Kaltenboeck A2, Mcintosh E1, Bach PB2
1University of Glasgow, Glasgow, UK, 2Memorial Sloan Kettering Cancer Center, New York, NY, USA

PHP316
K10
BIOSIMILAR UPTAKE IN THE UK- AN EVOLVING STORY?
Hendrich J, Boodhna T
WG Access, London, UK

PHP317
K11
REGULATORY REQUIREMENTS FOR NON-INTERVENTIONAL STUDIES COLLECTING PATIENT PREFERENCES AND EXPERIENCES IN FRANCE, GERMANY AND THE UK
Sluga O'Callaghan M, Ansquer V, Frugier G, Mai C
AplusA Real World, LYON, France

PHP318
K12
BRINGING MOLECULAR DIAGNOSTIC TESTS INTO CLINICAL PRACTICE: MAPPING THE EVIDENCE PATHWAY
Thompson AJ1, Allen AJ2, Bouttell J3, Gavan S1, Graziado S4, Hall PS5, McMeekin PM6, Smith AF7, Uchegbu I8, Vale L2, Payne K1
1The University of Manchester, Manchester, UK, 2Newcastle University, Newcastle upon Tyne, UK, 3The University of Glasgow, Glasgow, UK, 4Newcastle upon Tyne Hospitals, Newcastle upon Tyne, UK, 5University of Edinburgh, Edinburgh, UK, 6The University of Northumbria, Newcastle upon Tyne, UK, 7The University of Leeds, Leeds, UK, 8Imperial College London, London, UK

PHP319
K13
CONCEPT OF PHARMACEUTICAL CARE IN THE BRAZILIAN LEGISLATION
Chagas MO1, Porto CC2, Chaveiro N2, Chagas VO2, Assis DL1, Chagas FA3
1Universidade Federal de Goiás, Jataí, Goiás, Brazil, 2Universidade Federal de Goiás, Goiânia, Goiás, Brazil, 3Instituto Federal de Goiás, Jataí, Goiás, Brazil

PHP320
K14
WITHDRAWN

PHP321
K15
ALTERNATIVE REIMBURSEMENT MODELS FOR HIGH COST HEALTH TECHNOLOGIES
Serre D
Milliman, London, UK

PHP322
K16
THE IMPACT OF HEALTH POLICY ON THE PHARMACEUTICAL SUPPLY CHAIN IN FRANCE
Di Martinelly C1, Garonne C1, Duenas A2
1IESEG School of Management, LEM-CNRS (UMR 9221), Lille, France, 2ICN Business School, CEREFIGE, Nancy, France

PHP323
K17
POSSIBILITIES OF DOMESTIC PRODUCERS OF THE REPUBLIC OF KAZAKHSTAN IN THE FIELD OF MANUFACTURING ANTI-TUBERCULOSIS MEDICINES
Satayeva L.G., Nurmuchambetova A ParmankulovaT.N. Mirzabayeva N. LG
Kazakchstan National Medical University name Asfendiarov, Almaty, Kazakhstan

PHP324
K18
A CONCEPTUAL YET PRAGMATIC FRAMEWORK FOR VALUE-BASED AGREEMENTS
Lucas F1, Beers K2
1Pope Woodhead & Associates Ltd, St. Ives, UK, 2Huron, Boston, MA, USA

PHP325
K19
WHAT CAN BE DONE FOR ACCESS AND REIMBURSEMENT PROCESSES TO REWARD INNOVATION IN DIGITAL “BEYOND THE PILL” SOLUTIONS?
Focsa S
Executive Insight, Baar, Switzerland

PHP326
K20
WITHDRAWN

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.